A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02008227

Acronym

OAK

Enrollment

1225

Registered

2013-12-11

Start date

2014-03-11

Completion date

2019-01-09

Last updated

2019-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Brief summary

This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

Interventions

DRUGAtezolizumab

1200 mg IV infusion on Day 1 of each 21-day cycle

DRUGDocetaxel

75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC * Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens * Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen or combined modality (e.g., chemoradiation) regimen with curative intent * Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion criteria

* Known active or untreated central nervous system (CNS) metastases * Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome * History of autoimmune disease * History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted * Active hepatitis B or hepatitis C * Prior treatment with docetaxel * Prior treatment with cluster of differentiation 137 (CD137) agonists, anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA4), anti-programmed death-1 (anti-PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Who Died: PP-ITT	Baseline until death due to any cause (up to approximately 2.25 years)	—
Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP	Baseline until death due to any cause (up to approximately 2.25 years)	Percentage of participants who died among TC1/2/3 or IC1/2/3 subgroup of PP-ITT were reported. TC1 = presence of discernible programmed death-ligand 1 (PD-L1) staining of any intensity in \>/=1% and \<5% TCs; TC2: presence of discernible PD-L1 staining of any intensity in \>/=5% and \<50% TCs; TC3 = presence of discernible PD-L1 staining of any intensity in \>/=50% TCs; IC1 = presence of discernible PD-L1 staining of any intensity in ICs covering between \>/=1% and \<5% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC2 = presence of discernible PD-L1 staining of any intensity in ICs covering between \>/=5% and \<10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC3 = presence of discernible PD-L1 staining of any intensity in ICs covering \>/=10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma.
Overall Survival (OS): PP-ITT	Baseline until death due to any cause (up to approximately 2.25 years)	OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC1/2/3 or IC1/2/3 Subgroup of PP	Baseline until death due to any cause (up to approximately 2.25 years)	OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: SP-ITT	Baseline until death due to any cause (up to approximately 2.87 years)	OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC1/2/3 Or IC1/2/3 Subgroup of SP	Baseline until death from any cause (approximately 2.87 years)	OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC2/3 or IC2/3 Subgroup of SP	Baseline until death due to any cause (up to approximately 2.87 years)	OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC3 or IC3 Subgroup of SP	Baseline until death due to any cause (up to approximately 2.87 years)	OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.

Secondary

Measure	Time frame	Description
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab	Baseline up to approximately 2.25 years (assessed at predose [Hour {Hr} 0] on Day 1 of Cycles 1, 2, 3, 4, 8, 16, then every 8 cycles up to end of treatment (EOT) [approximately 2.25 years]; 120 days after EOT [approximately 2.25 years] [1 Cycle=21 days])	—
Maximum Observed Serum Atezolizumab Concentration (Cmax)	Predose (Hr 0), 30 minutes (min) post-infusion (infusion duration: 60 min) on Cycle 1 Day 1 (1 Cycle=21 days)	—
Minimum Observed Serum Atezolizumab Concentration (Cmin)	Predose (Hr 0) on Day 1 of Cycles 1, 2, 3, 4, 8, 16, 24, 32, EOT (approximately 2.25 years); 120 days after EOT (approximately 2.25 years) (1 Cycle=21 days)	—
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years) (1 Cycle = 21 days)	TTD in patient-reported lung cancer symptoms (pain in chest or in arm/shoulder, dyspnea, or cough) was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the symptoms. A \>/=10-point change in the score perceived by participants was considered as clinically significant. The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity.
EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	EORTC QLQ-C30 included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
EORTC QLQ-C30 Questionnaire Score: GHS Scale	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
EORTC QLQ-LC13 Questionnaire Score: Alopecia	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for alopecia.
EORTC QLQ-LC13 Questionnaire Score: Coughing	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for coughing.
Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT	Baseline up to PD or Death (up to approximately 2.25 years)	PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 millimeters (mm), or presence of new lesions.
EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for dyspnea.
EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for hemoptysis.
EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in arm or shoulder.
EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in chest.
EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for peripheral neuropathy.
EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in other parts.
EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for sore mouth.
PFS as Determined by Investigator Using RECIST v1.1: SP-ITT	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)	PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)	Objective response is defined as a complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
DOR as Determined by Investigator Using RECIST v1.1: SP ITT	From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)	DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.
EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)	QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for dysphagia.
Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP	Baseline up to PD or Death (up to approximately 2.25 years)	PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)	PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)	PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)	Objective response is defined as a complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)	Objective response is defined as a CR or PR as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT	From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)	DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.
DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)	DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.

Countries

Argentina, Austria, Brazil, Canada, Chile, Finland, France, Germany, Greece, Guatemala, Hungary, Italy, Japan, Netherlands, New Zealand, Norway, Panama, Poland, Portugal, Russia, Serbia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States

Participant flow

Pre-assignment details

Twelve hundred and twenty-five participants were randomized in the study and were considered the Secondary Population (SP), out of which first 850 randomized participants were considered the Primary Population (PP).

Participants by arm

Arm	Count
Docetaxel Docetaxel 75 milligrams per square meter (mg/m\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.	612
Atezolizumab Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.	613
Total	1,225

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Death	494	485
Overall Study	Lost to Follow-up	7	9
Overall Study	Study Terminated By Sponsor	44	83
Overall Study	Withdrawal by Subject	67	36

Baseline characteristics

Characteristic	Docetaxel	Total	Atezolizumab
Age, Continuous	62.9 Years STANDARD_DEVIATION 9.2	62.8 Years STANDARD_DEVIATION 9.5	62.7 Years STANDARD_DEVIATION 9.8
Ethnicity (NIH/OMB) Hispanic or Latino	42 Participants	90 Participants	48 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	541 Participants	1081 Participants	540 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	29 Participants	54 Participants	25 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	2 Participants	3 Participants	1 Participants
Race/Ethnicity, Customized Asian	125 Participants	249 Participants	124 Participants
Race/Ethnicity, Customized Black or African American	16 Participants	27 Participants	11 Participants
Race/Ethnicity, Customized Multiple	1 Participants	3 Participants	2 Participants
Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander	2 Participants	5 Participants	3 Participants
Race/Ethnicity, Customized Other	12 Participants	23 Participants	11 Participants
Race/Ethnicity, Customized Unknown	22 Participants	45 Participants	23 Participants
Race/Ethnicity, Customized White	432 Participants	870 Participants	438 Participants
Sex: Female, Male Female	233 Participants	467 Participants	234 Participants
Sex: Female, Male Male	379 Participants	758 Participants	379 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	535 / 578	541 / 609
serious Total, serious adverse events	180 / 578	200 / 609

Outcome results

Primary

OS: SP-ITT

OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.

Time frame: Baseline until death due to any cause (up to approximately 2.87 years)

Population: Secondary population (SP) ITT analysis set included all 1225 randomized participants regardless of whether they received any study drug.

Arm	Measure	Value (MEDIAN)
Docetaxel	OS: SP-ITT	9.8 Months
Atezolizumab	OS: SP-ITT	13.3 Months

Comparison: Stratified analysis based on the strata of IC levels per interactive voice/web response system (IxRS), the number of prior chemotherapy regimens per IxRS, and histology per electronic case report form (eCRF).p-value: 0.001295% CI: [0.7, 0.92]Log Rank

Primary

OS: TC1/2/3 or IC1/2/3 Subgroup of PP

Time frame: Baseline until death due to any cause (up to approximately 2.25 years)

Population: TC1/2/3 or IC1/2/3 subgroup of PP

Arm	Measure	Value (MEDIAN)
Docetaxel	OS: TC1/2/3 or IC1/2/3 Subgroup of PP	10.3 Months
Atezolizumab	OS: TC1/2/3 or IC1/2/3 Subgroup of PP	15.7 Months

Comparison: Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.p-value: 0.010295% CI: [0.58, 0.93]Log Rank

Comparison: Unstratified Analysisp-value: 0.005295% CI: [0.58, 0.91]Log Rank

Primary

OS: TC1/2/3 Or IC1/2/3 Subgroup of SP

Time frame: Baseline until death from any cause (approximately 2.87 years)

Population: TC1/2/3 Or IC1/2/3 Subgroup of SP.

Arm	Measure	Value (MEDIAN)
Docetaxel	OS: TC1/2/3 Or IC1/2/3 Subgroup of SP	10.8 Months
Atezolizumab	OS: TC1/2/3 Or IC1/2/3 Subgroup of SP	14.3 Months

Primary

OS: TC2/3 or IC2/3 Subgroup of SP

Time frame: Baseline until death due to any cause (up to approximately 2.87 years)

Population: TC2/3 or IC2/3 Subgroup of SP.

Arm	Measure	Value (MEDIAN)
Docetaxel	OS: TC2/3 or IC2/3 Subgroup of SP	11.4 Months
Atezolizumab	OS: TC2/3 or IC2/3 Subgroup of SP	16.6 Months

Primary

OS: TC3 or IC3 Subgroup of SP

Time frame: Baseline until death due to any cause (up to approximately 2.87 years)

Population: TC3 or IC3 Subgroup of SP.

Arm	Measure	Value (MEDIAN)
Docetaxel	OS: TC3 or IC3 Subgroup of SP	9.7 Months
Atezolizumab	OS: TC3 or IC3 Subgroup of SP	20.5 Months

Primary

Overall Survival (OS): PP-ITT

Time frame: Baseline until death due to any cause (up to approximately 2.25 years)

Population: The PP-ITT analysis set.

Arm	Measure	Value (MEDIAN)
Docetaxel	Overall Survival (OS): PP-ITT	9.6 Months
Atezolizumab	Overall Survival (OS): PP-ITT	13.8 Months

Comparison: Unstratified Analysisp-value: 0.000295% CI: [0.62, 0.86]Log Rank

Primary

Percentage of Participants Who Died: PP-ITT

Time frame: Baseline until death due to any cause (up to approximately 2.25 years)

Population: PP-ITT analysis set included the first 850 randomized ITT participants regardless of whether they received any study drug.

Arm	Measure	Value (NUMBER)
Docetaxel	Percentage of Participants Who Died: PP-ITT	70.1 Percentage of Participants
Atezolizumab	Percentage of Participants Who Died: PP-ITT	63.8 Percentage of Participants

Primary

Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP

Percentage of participants who died among TC1/2/3 or IC1/2/3 subgroup of PP-ITT were reported. TC1 = presence of discernible programmed death-ligand 1 (PD-L1) staining of any intensity in \>/=1% and \<5% TCs; TC2: presence of discernible PD-L1 staining of any intensity in \>/=5% and \<50% TCs; TC3 = presence of discernible PD-L1 staining of any intensity in \>/=50% TCs; IC1 = presence of discernible PD-L1 staining of any intensity in ICs covering between \>/=1% and \<5% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC2 = presence of discernible PD-L1 staining of any intensity in ICs covering between \>/=5% and \<10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC3 = presence of discernible PD-L1 staining of any intensity in ICs covering \>/=10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma.

Time frame: Baseline until death due to any cause (up to approximately 2.25 years)

Population: TC1/2/3 or IC1/2/3 subgroup within PP included ITT participants with the corresponding programmed death-ligand 1 (PD-L1) expression status.

Arm	Measure	Value (NUMBER)
Docetaxel	Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP	67.1 Percentage of Participants
Atezolizumab	Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP	62.7 Percentage of Participants

Secondary

DOR as Determined by Investigator Using RECIST v1.1: SP ITT

DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.

Time frame: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)

Population: The SP-ITT analysis set.

Arm	Measure	Value (MEDIAN)
Docetaxel	DOR as Determined by Investigator Using RECIST v1.1: SP ITT	6.3 Months
Atezolizumab	DOR as Determined by Investigator Using RECIST v1.1: SP ITT	23.9 Months

95% CI: [0.21, 0.48]

Secondary

DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP

Time frame: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)

Population: The TC1/2/3 or IC1/2/3 subgroup of PP

Arm	Measure	Value (MEDIAN)
Docetaxel	DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	6.2 Months
Atezolizumab	DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	16.0 Months

Comparison: Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.p-value: 0.000695% CI: [0.15, 0.62]Log Rank

Comparison: Unstratified Analysisp-value: 0.000395% CI: [0.22, 0.65]Log Rank

Secondary

Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT

Time frame: From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)

Population: The PP-ITT analysis set.

Arm	Measure	Value (MEDIAN)
Docetaxel	Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT	6.2 Months
Atezolizumab	Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT	16.3 Months

Comparison: Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.p-value: <0.000195% CI: [0.18, 0.55]Log Rank

Comparison: Unstratified Analysisp-value: <0.000195% CI: [0.21, 0.55]Log Rank

Secondary

EORTC QLQ-C30 Questionnaire Score: Functional Subscales

EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).

Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)

Population: The PP-ITT analysis set. Here, 'n' signifies those participants evaluated for this measure at specific time point for each group respectively. All 850 participants contributed to the endpoint but not all completed evaluation of every timepoint. Convention 'CxDx' refers to cycle number and day number.

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C20D1(n= 9, 80)	90.74 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C15D1(n= 16, 113)	86.25 Units on a scale	Standard Deviation 8.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C4D1(n= 223, 280)	79.60 Units on a scale	Standard Deviation 23
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C5D1(n= 166, 238)	79.32 Units on a scale	Standard Deviation 22.26
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C7D1(n= 88, 189)	77.61 Units on a scale	Standard Deviation 18.08
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C6D1(n= 151, 224)	78.15 Units on a scale	Standard Deviation 24.05
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C7D1(n= 87, 189)	80.65 Units on a scale	Standard Deviation 22.57
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C16D1(n= 13, 109)	85.13 Units on a scale	Standard Deviation 9.49
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C8D1(n= 72, 171)	81.94 Units on a scale	Standard Deviation 22.16
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: EOT(n= 267, 246)	63.59 Units on a scale	Standard Deviation 24.57
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C9D1(n= 50, 153)	82.00 Units on a scale	Standard Deviation 22.8
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C8D1(n= 72, 171)	89.58 Units on a scale	Standard Deviation 13.83
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C10D1(n= 47, 146)	81.21 Units on a scale	Standard Deviation 24.97
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: Pro Week 6 Pd(n= 0, 1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C11D1(n= 36, 134)	82.41 Units on a scale	Standard Deviation 26.11
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C17D1(n= 11, 98)	84.24 Units on a scale	Standard Deviation 12.03
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C12D1(n= 30, 132)	86.67 Units on a scale	Standard Deviation 18.77
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: Survival FU-1 (n= 2, 1)	36.67 Units on a scale	Standard Deviation 51.85
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C13D1(n= 18, 124)	89.81 Units on a scale	Standard Deviation 15.27
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C8D1(n= 71, 170)	78.45 Units on a scale	Standard Deviation 17.72
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C14D1(n= 17, 121)	86.27 Units on a scale	Standard Deviation 19.75
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: Baseline (n=388, 413)	70.92 Units on a scale	Standard Deviation 30.68
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C15D1(n= 15, 113)	93.33 Units on a scale	Standard Deviation 13.8
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C14D1(n= 17, 121)	92.16 Units on a scale	Standard Deviation 11.96
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C16D1(n= 12, 109)	84.72 Units on a scale	Standard Deviation 16.6
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C2D1 (n=339, 369)	69.91 Units on a scale	Standard Deviation 29.89
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C17D1(n= 11, 98)	87.88 Units on a scale	Standard Deviation 16.82
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C5D1(n= 166, 238)	86.04 Units on a scale	Standard Deviation 17.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C18D1(n= 10, 92)	86.67 Units on a scale	Standard Deviation 17.21
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C3D1 (n=256, 304)	74.61 Units on a scale	Standard Deviation 27.21
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C19D1(n= 9, 84)	88.89 Units on a scale	Standard Deviation 16.67
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C18D1(n= 10, 92)	82.67 Units on a scale	Standard Deviation 13.03
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C20D1(n= 9, 80)	81.48 Units on a scale	Standard Deviation 33.79
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C4D1 (n=224, 279)	73.36 Units on a scale	Standard Deviation 26.22
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C21D1(n= 9, 75)	85.19 Units on a scale	Standard Deviation 24.22
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C9D1(n= 50, 153)	79.07 Units on a scale	Standard Deviation 20.43
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C22D1(n= 8, 68)	85.42 Units on a scale	Standard Deviation 30.13
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C5D1 (n=167, 238)	74.35 Units on a scale	Standard Deviation 25
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C23D1(n= 8, 66)	91.67 Units on a scale	Standard Deviation 15.43
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C19D1(n= 9, 84)	87.41 Units on a scale	Standard Deviation 10.77
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C24D1(n= 5, 65)	80.00 Units on a scale	Standard Deviation 27.39
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C6D1 (n=151, 225)	73.62 Units on a scale	Standard Deviation 26.62
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C25D1(n= 3, 60)	77.78 Units on a scale	Standard Deviation 38.49
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C9D1(n= 50, 153)	90.00 Units on a scale	Standard Deviation 14.29
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C26D1(n= 3, 55)	77.78 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C7D1 (n=88, 190)	77.27 Units on a scale	Standard Deviation 23.19
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C27D1(n= 3, 52)	88.89 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C15D1(n= 15, 113)	93.33 Units on a scale	Standard Deviation 10.54
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C28D1(n= 1, 48)	100.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C8D1 (n=72, 170)	73.61 Units on a scale	Standard Deviation 26.5
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C29D1(n= 2, 40)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C20D1(n= 9, 80)	81.48 Units on a scale	Standard Deviation 18.19
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C30D1(n= 1, 31)	100.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C9D1 (n=50, 153)	77.67 Units on a scale	Standard Deviation 24.42
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C10D1(n= 47, 146)	91.13 Units on a scale	Standard Deviation 11.96
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C10D1 (n=47, 145)	78.72 Units on a scale	Standard Deviation 27.74
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C21D1(n= 9, 75)	87.41 Units on a scale	Standard Deviation 11.28
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C11D1 (n=37, 134)	80.63 Units on a scale	Standard Deviation 24.69
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C2D1(n= 343, 369)	72.64 Units on a scale	Standard Deviation 22
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C12D1 (n=30, 132)	81.11 Units on a scale	Standard Deviation 22.2
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C22D1(n= 8, 69)	82.50 Units on a scale	Standard Deviation 19.82
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C13D1 (n=19, 124)	84.21 Units on a scale	Standard Deviation 18.82
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: EOT(n= 264, 245)	69.51 Units on a scale	Standard Deviation 30.65
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C11D1(n= 36, 134)	92.59 Units on a scale	Standard Deviation 10.87
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: Pro Week 6 Pd(n= 0, 1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C14D1 (n=18, 121)	78.70 Units on a scale	Standard Deviation 21.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: Survival FU-1 (n= 2, 1)	83.33 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C16D1(n= 12, 109)	97.22 Units on a scale	Standard Deviation 6.49
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C21D1(n= 9, 75)	87.04 Units on a scale	Standard Deviation 23.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C15D1 (n=16, 113)	83.33 Units on a scale	Standard Deviation 14.91
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C22D1(n= 8, 68)	89.58 Units on a scale	Standard Deviation 12.4
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C2D1 (n= 341, 363)	83.38 Units on a scale	Standard Deviation 21.64
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C23D1(n= 8, 66)	95.83 Units on a scale	Standard Deviation 7.72
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C16D1 (n=13, 109)	85.90 Units on a scale	Standard Deviation 19.06
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C24D1(n= 5, 64)	83.33 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C23D1(n= 8, 66)	85.00 Units on a scale	Standard Deviation 13.21
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C25D1(n= 3, 60)	72.22 Units on a scale	Standard Deviation 25.46
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C17D1 (n=11, 98)	80.30 Units on a scale	Standard Deviation 20.84
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C26D1(n= 3, 55)	77.78 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C12D1(n= 30, 132)	91.11 Units on a scale	Standard Deviation 12.17
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C27D1(n= 3, 52)	88.89 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C18D1 (n=10, 92)	80.00 Units on a scale	Standard Deviation 26.99
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C28D1(n= 1, 48)	100.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C24D1(n= 5, 64)	80.00 Units on a scale	Standard Deviation 18.26
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C29D1(n= 2, 40)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C19D1 (n=9, 84)	85.19 Units on a scale	Standard Deviation 22.74
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C30D1(n= 1, 31)	100.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C3D1(n= 255, 304)	74.98 Units on a scale	Standard Deviation 21.6
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C20D1 (n=9, 80)	79.63 Units on a scale	Standard Deviation 29.79
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C25D1(n= 3, 60)	82.22 Units on a scale	Standard Deviation 16.78
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C21D1 (n=9, 75)	85.19 Units on a scale	Standard Deviation 15.47
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C13D1(n= 18, 124)	90.74 Units on a scale	Standard Deviation 11.75
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C22D1 (n=8, 69)	79.17 Units on a scale	Standard Deviation 35.36
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C26D1(n= 3, 55)	75.56 Units on a scale	Standard Deviation 3.85
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C23D1 (n=8, 66)	85.42 Units on a scale	Standard Deviation 20.77
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C6D1(n= 151, 224)	86.09 Units on a scale	Standard Deviation 18.2
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: EOT (n= 266, 246)	78.82 Units on a scale	Standard Deviation 24.54
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C24D1 (n=5, 65)	70.00 Units on a scale	Standard Deviation 34.16
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C4D1(n= 224, 277)	75.72 Units on a scale	Standard Deviation 19.05
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: Survival FU 1 (n= 2, 1)	50.00 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C25D1 (n=3, 60)	77.78 Units on a scale	Standard Deviation 38.49
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: Baseline (n= 390, 411)	75.83 Units on a scale	Standard Deviation 22.59
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C17D1(n= 11, 98)	96.97 Units on a scale	Standard Deviation 6.74
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C2D1(n= 341, 363)	78.06 Units on a scale	Standard Deviation 22.63
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C19D1(n= 9, 84)	92.59 Units on a scale	Standard Deviation 12.11
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C3D1(n= 256, 305)	79.70 Units on a scale	Standard Deviation 22.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C10D1(n= 47, 146)	79.29 Units on a scale	Standard Deviation 19.96
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C4D1(n= 224, 280)	81.67 Units on a scale	Standard Deviation 20.36
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C18D1(n= 10, 92)	91.67 Units on a scale	Standard Deviation 11.79
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C5D1(n= 166, 238)	80.52 Units on a scale	Standard Deviation 20.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C26D1 (n=3, 55)	83.33 Units on a scale	Standard Deviation 28.87
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C6D1(n= 151, 224)	81.73 Units on a scale	Standard Deviation 20.5
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C27D1(n= 2, 52)	76.67 Units on a scale	Standard Deviation 4.71
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C7D1(n= 87, 189)	81.42 Units on a scale	Standard Deviation 22
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C27D1 (n=3, 52)	88.89 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C8D1(n= 72, 171)	84.38 Units on a scale	Standard Deviation 18.66
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C4D1(n= 224, 281)	84.82 Units on a scale	Standard Deviation 19.27
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C9D1(n= 50, 153)	86.00 Units on a scale	Standard Deviation 17.93
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C28D1 (n=1, 49)	100.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C10D1(n= 47, 146)	84.93 Units on a scale	Standard Deviation 17.69
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C28D1(n= 2, 49)	65.00 Units on a scale	Standard Deviation 21.21
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C11D1(n= 36, 134)	89.12 Units on a scale	Standard Deviation 15.15
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C29D1 (n=2, 40)	66.67 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C12D1(n= 30, 132)	86.94 Units on a scale	Standard Deviation 14.79
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C11D1(n= 37, 134)	81.44 Units on a scale	Standard Deviation 20.85
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C13D1(n= 18, 123)	89.35 Units on a scale	Standard Deviation 14.52
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C30D1 (n=1, 31)	100.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C14D1(n= 17, 121)	86.27 Units on a scale	Standard Deviation 15.57
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C29D1(n= 2, 40)	56.67 Units on a scale	Standard Deviation 33
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C15D1(n= 15, 113)	90.00 Units on a scale	Standard Deviation 14.16
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C31D1(n=0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C16D1(n= 12, 109)	88.89 Units on a scale	Standard Deviation 16.02
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C5D1(n= 167, 238)	77.30 Units on a scale	Standard Deviation 19
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C17D1(n= 11, 98)	88.64 Units on a scale	Standard Deviation 17.59
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C32D1(n=0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C18D1(n= 10, 92)	87.50 Units on a scale	Standard Deviation 19.35
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C30D1(n= 1, 31)	80.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C19D1(n= 9, 84)	87.96 Units on a scale	Standard Deviation 19.14
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C33D1(n=0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C20D1(n=9, 80)	76.85 Units on a scale	Standard Deviation 34.3
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C12D1(n= 30, 132)	82.22 Units on a scale	Standard Deviation 15.69
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C21D1(n= 9, 75)	83.33 Units on a scale	Standard Deviation 26.68
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C34D1(n=0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C22D1(n= 8, 68)	76.74 Units on a scale	Standard Deviation 32.6
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C23D1(n= 8, 66)	89.58 Units on a scale	Standard Deviation 15.91
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C35D1(n=0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C24D1(n=5, 65)	78.33 Units on a scale	Standard Deviation 33.12
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C7D1(n= 87, 189)	87.55 Units on a scale	Standard Deviation 16.32
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C25D1(n= 3, 60)	100.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C36D1(n=0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C26D1(n= 3, 55)	86.11 Units on a scale	Standard Deviation 12.73
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C27D1(n= 3, 52)	100.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C37D1(n=0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C28D1(n= 1, 48)	100.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C13D1(n= 19, 124)	87.37 Units on a scale	Standard Deviation 9.66
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C29D1(n= 2, 40)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C38D1(n=0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C30D1(n= 1, 31)	100.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: EOT(n=266, 246)	58.52 Units on a scale	Standard Deviation 32.99
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C6D1(n= 151, 225)	74.77 Units on a scale	Standard Deviation 19.26
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: Pro Week 6 Pd (n=0, 1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: Survival FU-1 (n=2,1)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C14D1(n= 18, 121)	85.56 Units on a scale	Standard Deviation 9.5
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: Baseline (n= 389, 411)	74.16 Units on a scale	Standard Deviation 26.92
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: EOT (n= 265, 246)	73.78 Units on a scale	Standard Deviation 26.29
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C2D1(n= 340, 363)	74.51 Units on a scale	Standard Deviation 26.5
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C3D1(n= 256, 305)	84.05 Units on a scale	Standard Deviation 19.82
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: Survival FU-1 (n= 2,1)	25.00 Units on a scale	Standard Deviation 35.36
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C3D1(n= 255, 305)	78.37 Units on a scale	Standard Deviation 25.3
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: Baseline (n= 390, 413)	73.27 Units on a scale	Standard Deviation 22.58
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: Baseline (n= 390, 411)	83.38 Units on a scale	Standard Deviation 20.68
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: Baseline (n= 390, 413)	74.46 Units on a scale	Standard Deviation 20.66
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: Baseline (n= 390, 411)	85.16 Units on a scale	Standard Deviation 19.16
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C2D1 (n= 341, 363)	84.94 Units on a scale	Standard Deviation 19.3
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C3D1(n= 256, 305)	86.28 Units on a scale	Standard Deviation 17.32
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C4D1(n= 224, 281)	85.35 Units on a scale	Standard Deviation 19.87
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C5D1(n= 166, 238)	84.38 Units on a scale	Standard Deviation 19.73
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C6D1(n= 151, 224)	84.45 Units on a scale	Standard Deviation 20.27
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C7D1(n= 87, 189)	84.74 Units on a scale	Standard Deviation 18.93
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C8D1(n= 72, 171)	85.58 Units on a scale	Standard Deviation 18.87
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C2D1(n= 343, 369)	71.70 Units on a scale	Standard Deviation 22.49
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C3D1(n= 255, 304)	76.19 Units on a scale	Standard Deviation 19.48
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C4D1(n= 224, 277)	76.79 Units on a scale	Standard Deviation 19.95
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C5D1(n= 167, 238)	77.79 Units on a scale	Standard Deviation 19.89
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C6D1(n= 151, 225)	78.93 Units on a scale	Standard Deviation 18.76
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C7D1(n= 88, 189)	79.20 Units on a scale	Standard Deviation 18.42
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C8D1(n= 71, 170)	78.87 Units on a scale	Standard Deviation 18.91
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C9D1(n= 50, 153)	85.95 Units on a scale	Standard Deviation 18.65
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C10D1(n= 47, 146)	86.53 Units on a scale	Standard Deviation 19.31
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C11D1(n= 36, 134)	85.95 Units on a scale	Standard Deviation 19.91
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C12D1(n= 30, 132)	84.22 Units on a scale	Standard Deviation 20.52
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C13D1(n= 18, 124)	84.27 Units on a scale	Standard Deviation 21.5
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C9D1(n= 50, 153)	79.46 Units on a scale	Standard Deviation 18.75
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C10D1(n= 47, 146)	79.41 Units on a scale	Standard Deviation 18.85
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C11D1(n= 37, 134)	79.09 Units on a scale	Standard Deviation 20.5
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C12D1(n= 30, 132)	79.72 Units on a scale	Standard Deviation 18.84
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C13D1(n= 19, 124)	80.48 Units on a scale	Standard Deviation 19.33
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C14D1(n= 18, 121)	80.33 Units on a scale	Standard Deviation 17.55
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C15D1(n= 16, 113)	79.88 Units on a scale	Standard Deviation 18.64
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C16D1(n= 13, 109)	78.82 Units on a scale	Standard Deviation 21.32
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C17D1(n= 11, 98)	78.57 Units on a scale	Standard Deviation 20.89
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C14D1(n= 17, 121)	85.67 Units on a scale	Standard Deviation 18.3
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C18D1(n= 10, 92)	79.64 Units on a scale	Standard Deviation 19.92
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C19D1(n= 9, 84)	78.97 Units on a scale	Standard Deviation 20.48
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C20D1(n= 9, 80)	79.19 Units on a scale	Standard Deviation 20.26
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C21D1(n= 9, 75)	78.67 Units on a scale	Standard Deviation 20.68
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C15D1(n= 15, 113)	85.10 Units on a scale	Standard Deviation 19.08
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C22D1(n= 8, 69)	82.51 Units on a scale	Standard Deviation 16.92
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C23D1(n= 8, 66)	80.81 Units on a scale	Standard Deviation 17.56
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C24D1(n= 5, 64)	81.41 Units on a scale	Standard Deviation 17.69
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C25D1(n= 3, 60)	83.22 Units on a scale	Standard Deviation 16.67
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C26D1(n= 3, 55)	80.12 Units on a scale	Standard Deviation 17.43
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C16D1(n= 12, 109)	85.32 Units on a scale	Standard Deviation 21.12
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C17D1(n= 11, 98)	85.37 Units on a scale	Standard Deviation 20.48
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C27D1(n= 2, 52)	81.89 Units on a scale	Standard Deviation 16.9
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C28D1(n= 2, 49)	84.15 Units on a scale	Standard Deviation 14.41
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C29D1(n= 2, 40)	83.00 Units on a scale	Standard Deviation 14.87
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C30D1(n= 1, 31)	83.01 Units on a scale	Standard Deviation 15.67
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C31D1(n= 0, 24)	78.61 Units on a scale	Standard Deviation 17.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C32D1(n= 0, 22)	75.15 Units on a scale	Standard Deviation 18.42
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C33D1(n= 0, 16)	77.92 Units on a scale	Standard Deviation 17.84
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C34D1(n= 0, 14)	75.24 Units on a scale	Standard Deviation 19.47
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C35D1(n= 0, 12)	73.89 Units on a scale	Standard Deviation 20.78
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C36D1(n= 0, 8)	83.33 Units on a scale	Standard Deviation 17.46
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C37D1(n= 0, 5)	74.67 Units on a scale	Standard Deviation 14.45
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: C38D1(n= 0, 2)	86.67 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: EOT(n= 267, 246)	64.78 Units on a scale	Standard Deviation 26.47
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: Pro Week 6 Pd(n= 0, 1)	46.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Physical: Survival FU-1 (n= 2, 1)	46.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: Baseline (n=388, 413)	73.61 Units on a scale	Standard Deviation 29.13
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C2D1 (n=339, 369)	68.29 Units on a scale	Standard Deviation 31.5
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C3D1 (n=256, 304)	75.27 Units on a scale	Standard Deviation 27.28
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C4D1 (n=224, 279)	76.70 Units on a scale	Standard Deviation 25.27
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C5D1 (n=167, 238)	76.05 Units on a scale	Standard Deviation 26.97
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C6D1 (n=151, 225)	77.70 Units on a scale	Standard Deviation 26.78
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C7D1 (n=88, 190)	79.04 Units on a scale	Standard Deviation 24.97
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C8D1 (n=72, 170)	77.35 Units on a scale	Standard Deviation 25.22
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C9D1 (n=50, 153)	79.30 Units on a scale	Standard Deviation 25.36
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C10D1 (n=47, 145)	81.38 Units on a scale	Standard Deviation 24.34
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C11D1 (n=37, 134)	78.61 Units on a scale	Standard Deviation 27.01
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C12D1 (n=30, 132)	79.80 Units on a scale	Standard Deviation 25.97
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C13D1 (n=19, 124)	79.44 Units on a scale	Standard Deviation 26.55
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C14D1 (n=18, 121)	79.48 Units on a scale	Standard Deviation 24.98
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C15D1 (n=16, 113)	79.20 Units on a scale	Standard Deviation 25.05
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C16D1 (n=13, 109)	76.45 Units on a scale	Standard Deviation 27.89
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C17D1 (n=11, 98)	76.02 Units on a scale	Standard Deviation 29.22
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C18D1 (n=10, 92)	77.17 Units on a scale	Standard Deviation 27.59
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C19D1 (n=9, 84)	78.17 Units on a scale	Standard Deviation 28.46
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C20D1 (n=9, 80)	78.54 Units on a scale	Standard Deviation 26.01
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C21D1 (n=9, 75)	77.33 Units on a scale	Standard Deviation 28.29
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C22D1 (n=8, 69)	81.64 Units on a scale	Standard Deviation 26.68
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C23D1 (n=8, 66)	80.30 Units on a scale	Standard Deviation 26.13
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C24D1 (n=5, 65)	78.72 Units on a scale	Standard Deviation 26.92
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C18D1(n= 10, 92)	82.97 Units on a scale	Standard Deviation 20.52
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C19D1(n= 9, 84)	83.53 Units on a scale	Standard Deviation 20.12
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C25D1 (n=3, 60)	79.44 Units on a scale	Standard Deviation 27.34
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C26D1 (n=3, 55)	76.97 Units on a scale	Standard Deviation 27.31
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C27D1 (n=3, 52)	80.77 Units on a scale	Standard Deviation 26.89
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C28D1 (n=1, 49)	82.99 Units on a scale	Standard Deviation 22.69
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C29D1 (n=2, 40)	83.33 Units on a scale	Standard Deviation 24.75
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C30D1 (n=1, 31)	81.72 Units on a scale	Standard Deviation 24.1
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C31D1(n=0, 24)	79.86 Units on a scale	Standard Deviation 25.53
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C32D1(n=0, 22)	75.00 Units on a scale	Standard Deviation 27.58
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C33D1(n=0, 16)	66.67 Units on a scale	Standard Deviation 34.43
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C34D1(n=0, 14)	69.05 Units on a scale	Standard Deviation 33.88
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C35D1(n=0, 12)	69.44 Units on a scale	Standard Deviation 32.44
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C36D1(n=0, 8)	87.50 Units on a scale	Standard Deviation 17.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C37D1(n=0, 5)	76.67 Units on a scale	Standard Deviation 22.36
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: C38D1(n=0, 2)	100.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: EOT(n=266, 246)	60.03 Units on a scale	Standard Deviation 33.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: Pro Week 6 Pd (n=0, 1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Role: Survival FU-1 (n=2,1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: Baseline (n= 389, 411)	77.41 Units on a scale	Standard Deviation 26.13
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C2D1(n= 340, 363)	76.86 Units on a scale	Standard Deviation 26.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C20D1(n= 9, 80)	82.29 Units on a scale	Standard Deviation 22.87
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C3D1(n= 255, 305)	81.15 Units on a scale	Standard Deviation 23.7
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C4D1(n= 223, 280)	81.31 Units on a scale	Standard Deviation 24.15
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C5D1(n= 166, 238)	82.00 Units on a scale	Standard Deviation 24.39
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C6D1(n= 151, 224)	81.99 Units on a scale	Standard Deviation 23.8
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C7D1(n= 87, 189)	82.80 Units on a scale	Standard Deviation 22.54
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C8D1(n= 72, 171)	81.19 Units on a scale	Standard Deviation 23.95
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C9D1(n= 50, 153)	83.77 Units on a scale	Standard Deviation 22.29
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C10D1(n= 47, 146)	83.79 Units on a scale	Standard Deviation 22.99
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C11D1(n= 36, 134)	81.47 Units on a scale	Standard Deviation 25.42
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C12D1(n= 30, 132)	82.95 Units on a scale	Standard Deviation 24.58
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C13D1(n= 18, 124)	84.27 Units on a scale	Standard Deviation 22.82
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C14D1(n= 17, 121)	84.16 Units on a scale	Standard Deviation 22.55
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C15D1(n= 15, 113)	83.92 Units on a scale	Standard Deviation 22.26
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C16D1(n= 12, 109)	82.72 Units on a scale	Standard Deviation 24.73
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C17D1(n= 11, 98)	82.99 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C18D1(n= 10, 92)	81.34 Units on a scale	Standard Deviation 24.06
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C19D1(n= 9, 84)	81.94 Units on a scale	Standard Deviation 25.9
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C20D1(n= 9, 80)	81.46 Units on a scale	Standard Deviation 24.73
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C21D1(n= 9, 75)	78.67 Units on a scale	Standard Deviation 27.88
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C22D1(n= 8, 68)	84.31 Units on a scale	Standard Deviation 25.41
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C23D1(n= 8, 66)	80.56 Units on a scale	Standard Deviation 26.24
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C24D1(n= 5, 65)	80.77 Units on a scale	Standard Deviation 25.38
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C25D1(n= 3, 60)	81.39 Units on a scale	Standard Deviation 27.8
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C26D1(n= 3, 55)	79.70 Units on a scale	Standard Deviation 27.53
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C27D1(n= 3, 52)	82.05 Units on a scale	Standard Deviation 25.32
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C28D1(n= 1, 48)	84.03 Units on a scale	Standard Deviation 24.3
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C29D1(n= 2, 40)	82.92 Units on a scale	Standard Deviation 24.6
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C30D1(n= 1, 31)	79.57 Units on a scale	Standard Deviation 27.79
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C31D1(n= 0, 24)	79.17 Units on a scale	Standard Deviation 26.12
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C32D1(n= 0, 22)	73.48 Units on a scale	Standard Deviation 30.71
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C33D1(n= 0, 16)	73.96 Units on a scale	Standard Deviation 32.19
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C34D1(n= 0, 14)	67.86 Units on a scale	Standard Deviation 34.88
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C35D1(n= 0, 12)	70.83 Units on a scale	Standard Deviation 31.88
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C36D1(n= 0, 8)	87.50 Units on a scale	Standard Deviation 17.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C37D1(n= 0, 5)	80.00 Units on a scale	Standard Deviation 18.26
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: C38D1(n= 0, 2)	100.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: EOT(n= 264, 245)	70.00 Units on a scale	Standard Deviation 30.05
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: Pro Week 6 Pd(n= 0, 1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Social: Survival FU-1 (n= 2, 1)	16.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C21D1(n= 9, 75)	83.78 Units on a scale	Standard Deviation 20.32
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C22D1(n= 8, 68)	84.56 Units on a scale	Standard Deviation 21.03
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C23D1(n= 8, 66)	84.09 Units on a scale	Standard Deviation 20.55
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C24D1(n= 5, 64)	83.85 Units on a scale	Standard Deviation 23.56
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C25D1(n= 3, 60)	83.61 Units on a scale	Standard Deviation 21.59
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C26D1(n= 3, 55)	82.73 Units on a scale	Standard Deviation 21.51
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C27D1(n= 3, 52)	85.26 Units on a scale	Standard Deviation 20.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C28D1(n= 1, 48)	85.07 Units on a scale	Standard Deviation 20.98
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C29D1(n= 2, 40)	83.75 Units on a scale	Standard Deviation 20.84
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C30D1(n= 1, 31)	86.02 Units on a scale	Standard Deviation 20.68
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C31D1(n= 0, 24)	80.56 Units on a scale	Standard Deviation 21.23
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C32D1(n= 0, 22)	82.58 Units on a scale	Standard Deviation 22.11
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C33D1(n= 0,16)	77.08 Units on a scale	Standard Deviation 25.73
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C34D1(n= 0, 14)	80.95 Units on a scale	Standard Deviation 24.33
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C35D1(n= 0, 12)	76.39 Units on a scale	Standard Deviation 21.86
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C36D1(n= 0, 8)	83.33 Units on a scale	Standard Deviation 15.43
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C37D1(n= 0, 5)	83.33 Units on a scale	Standard Deviation 16.67
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: C38D1(n= 0, 2)	91.67 Units on a scale	Standard Deviation 11.79
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: EOT (n= 266, 246)	78.52 Units on a scale	Standard Deviation 22.5
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: Pro Week 6 Pd(n= 0,1)	83.33 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Cognitive: Survival FU 1 (n= 2, 1)	0.00 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: Baseline (n= 390, 411)	76.55 Units on a scale	Standard Deviation 21.77
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C2D1(n= 341, 363)	79.47 Units on a scale	Standard Deviation 20.72
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C3D1(n= 256, 305)	82.71 Units on a scale	Standard Deviation 17.45
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C4D1(n= 224, 280)	83.69 Units on a scale	Standard Deviation 17.7
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C5D1(n= 166, 238)	81.99 Units on a scale	Standard Deviation 19.22
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C6D1(n= 151, 224)	82.70 Units on a scale	Standard Deviation 19.91
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C7D1(n= 87, 189)	83.77 Units on a scale	Standard Deviation 17.71
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C8D1(n= 72, 171)	83.63 Units on a scale	Standard Deviation 19.4
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C9D1(n= 50, 153)	85.62 Units on a scale	Standard Deviation 18.72
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C10D1(n= 47, 146)	84.13 Units on a scale	Standard Deviation 19.74
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C11D1(n= 36, 134)	84.16 Units on a scale	Standard Deviation 18.14
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C12D1(n= 30, 132)	84.34 Units on a scale	Standard Deviation 20.1
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C13D1(n= 18, 123)	84.35 Units on a scale	Standard Deviation 19.75
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C14D1(n= 17, 121)	84.25 Units on a scale	Standard Deviation 19.11
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C15D1(n= 15, 113)	83.87 Units on a scale	Standard Deviation 20.04
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C16D1(n= 12, 109)	82.11 Units on a scale	Standard Deviation 22.59
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C17D1(n= 11, 98)	83.25 Units on a scale	Standard Deviation 19.5
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C18D1(n= 10, 92)	82.52 Units on a scale	Standard Deviation 21.11
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C19D1(n= 9, 84)	81.42 Units on a scale	Standard Deviation 20.55
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C20D1(n=9, 80)	83.19 Units on a scale	Standard Deviation 18.9
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C21D1(n= 9, 75)	84.19 Units on a scale	Standard Deviation 17.58
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C22D1(n= 8, 68)	86.03 Units on a scale	Standard Deviation 16.44
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C23D1(n= 8, 66)	87.00 Units on a scale	Standard Deviation 17.55
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C24D1(n=5, 65)	83.72 Units on a scale	Standard Deviation 19.18
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C25D1(n= 3, 60)	83.66 Units on a scale	Standard Deviation 18.77
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C26D1(n= 3, 55)	85.15 Units on a scale	Standard Deviation 19.69
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C27D1(n= 3, 52)	86.38 Units on a scale	Standard Deviation 18.38
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C28D1(n= 1, 48)	86.92 Units on a scale	Standard Deviation 17.51
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C29D1(n= 2, 40)	87.50 Units on a scale	Standard Deviation 16.45
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C30D1(n= 1, 31)	89.79 Units on a scale	Standard Deviation 15.62
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C31D1(n= 0, 24)	85.76 Units on a scale	Standard Deviation 18.3
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C32D1(n= 0, 22)	82.95 Units on a scale	Standard Deviation 20.81
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C33D1(n= 0, 16)	81.25 Units on a scale	Standard Deviation 25.37
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C34D1(n= 0, 14)	82.14 Units on a scale	Standard Deviation 25.29
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C35D1(n= 0, 12)	83.33 Units on a scale	Standard Deviation 21.61
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C36D1(n= 0, 8)	95.83 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C37D1(n= 0, 5)	90.00 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: C38D1(n= 0, 2)	83.33 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: EOT (n= 265, 246)	73.92 Units on a scale	Standard Deviation 23.74
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: Pro Week 6 Pd(n= 0,1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Functional Subscales	Emotional: Survival FU-1 (n= 2,1)	33.33 Units on a scale	—

Secondary

EORTC QLQ-C30 Questionnaire Score: GHS Scale

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C21D1(n= 9, 75)	60.19 Units on a scale	Standard Deviation 29.98
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C11D1(n= 36, 133)	69.68 Units on a scale	Standard Deviation 17.15
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C22D1(n= 8, 68)	54.17 Units on a scale	Standard Deviation 24.8
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C6D1(n= 151, 223)	64.51 Units on a scale	Standard Deviation 19.59
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C23D1(n= 8, 66)	62.50 Units on a scale	Standard Deviation 19.42
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C12D1(n= 30, 131)	66.67 Units on a scale	Standard Deviation 18.05
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C24D1(n= 5, 65)	70.00 Units on a scale	Standard Deviation 27.39
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C2D1(n= 339, 361)	59.56 Units on a scale	Standard Deviation 22.15
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C25D1(n= 3, 60)	66.67 Units on a scale	Standard Deviation 28.87
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C13D1(n= 18, 124)	69.91 Units on a scale	Standard Deviation 14.33
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C26D1(n= 3, 55)	66.67 Units on a scale	Standard Deviation 28.87
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C7D1(n= 87, 187)	64.85 Units on a scale	Standard Deviation 18.13
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C27D1(n= 3, 52)	66.67 Units on a scale	Standard Deviation 28.87
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C14D1(n= 17, 120)	69.61 Units on a scale	Standard Deviation 14.71
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C28D1(n= 2, 48)	87.50 Units on a scale	Standard Deviation 17.68
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C4D1(n= 222, 279)	63.51 Units on a scale	Standard Deviation 20.67
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C29D1(n= 2, 40)	91.67 Units on a scale	Standard Deviation 11.79
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C15D1(n= 15, 113)	69.44 Units on a scale	Standard Deviation 17.16
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C30D1(n= 1, 30)	83.33 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C8D1(n= 72, 169)	62.73 Units on a scale	Standard Deviation 20.22
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C16D1(n= 12, 109)	62.50 Units on a scale	Standard Deviation 15.69
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: Baseline (n= 387, 410)	60.55 Units on a scale	Standard Deviation 22.25
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C17D1(n= 10, 98)	61.67 Units on a scale	Standard Deviation 19.72
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C9D1(n= 50, 152)	67.17 Units on a scale	Standard Deviation 18.93
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C18D1(n= 10, 92)	61.67 Units on a scale	Standard Deviation 21.23
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C5D1(n= 166, 235)	64.01 Units on a scale	Standard Deviation 18.37
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C19D1(n= 9, 84)	65.74 Units on a scale	Standard Deviation 21.43
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: EOT(n= 262, 245)	51.69 Units on a scale	Standard Deviation 24.02
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C10D1(n= 47, 145)	66.84 Units on a scale	Standard Deviation 18.67
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C20D1(n= 9, 80)	62.04 Units on a scale	Standard Deviation 26.72
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: Survival FU 1 (n= 2, 1)	58.33 Units on a scale	Standard Deviation 35.36
Docetaxel	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C3D1(n= 255, 304)	64.64 Units on a scale	Standard Deviation 18.66
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: Survival FU 1 (n= 2, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: Baseline (n= 387, 410)	61.24 Units on a scale	Standard Deviation 22.31
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C2D1(n= 339, 361)	58.93 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C3D1(n= 255, 304)	64.61 Units on a scale	Standard Deviation 20.74
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C4D1(n= 222, 279)	65.11 Units on a scale	Standard Deviation 21.36
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C5D1(n= 166, 235)	66.35 Units on a scale	Standard Deviation 19.84
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C6D1(n= 151, 223)	65.73 Units on a scale	Standard Deviation 21.42
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C7D1(n= 87, 187)	66.93 Units on a scale	Standard Deviation 19.61
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C8D1(n= 72, 169)	67.36 Units on a scale	Standard Deviation 19.45
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C9D1(n= 50, 152)	68.09 Units on a scale	Standard Deviation 19.46
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C10D1(n= 47, 145)	69.37 Units on a scale	Standard Deviation 20.9
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C11D1(n= 36, 133)	68.17 Units on a scale	Standard Deviation 21.24
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C12D1(n= 30, 131)	68.32 Units on a scale	Standard Deviation 20.42
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C13D1(n= 18, 124)	67.74 Units on a scale	Standard Deviation 22.52
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C14D1(n= 17, 120)	67.01 Units on a scale	Standard Deviation 20.62
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C15D1(n= 15, 113)	68.66 Units on a scale	Standard Deviation 20.21
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C16D1(n= 12, 109)	67.97 Units on a scale	Standard Deviation 21.67
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C17D1(n= 10, 98)	68.62 Units on a scale	Standard Deviation 19.84
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C18D1(n= 10, 92)	68.57 Units on a scale	Standard Deviation 18.86
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C19D1(n= 9, 84)	68.25 Units on a scale	Standard Deviation 20.1
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C20D1(n= 9, 80)	68.12 Units on a scale	Standard Deviation 20.1
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C21D1(n= 9, 75)	66.56 Units on a scale	Standard Deviation 21.55
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C22D1(n= 8, 68)	73.28 Units on a scale	Standard Deviation 17.13
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C23D1(n= 8, 66)	70.45 Units on a scale	Standard Deviation 18.09
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C24D1(n= 5, 65)	69.36 Units on a scale	Standard Deviation 19.27
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C25D1(n= 3, 60)	69.03 Units on a scale	Standard Deviation 19.23
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C26D1(n= 3, 55)	68.64 Units on a scale	Standard Deviation 20.6
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C27D1(n= 3, 52)	68.91 Units on a scale	Standard Deviation 21.84
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C28D1(n= 2, 48)	71.87 Units on a scale	Standard Deviation 20.6
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C29D1(n= 2, 40)	72.71 Units on a scale	Standard Deviation 20.06
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C30D1(n= 1, 30)	75.28 Units on a scale	Standard Deviation 18.63
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C31D1(n= 0, 24)	71.53 Units on a scale	Standard Deviation 21.13
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C32D1(n= 0, 22)	70.45 Units on a scale	Standard Deviation 20.21
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C34D1(n= 0, 14)	68.45 Units on a scale	Standard Deviation 26.19
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C35D1(n= 0, 12)	69.44 Units on a scale	Standard Deviation 26.43
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C36D1(n= 0, 8)	80.21 Units on a scale	Standard Deviation 16.63
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C37D1(n= 0, 5)	76.67 Units on a scale	Standard Deviation 19
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C38D1(n= 0, 2)	91.67 Units on a scale	Standard Deviation 11.79
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: EOT(n= 262, 245)	52.82 Units on a scale	Standard Deviation 24.48
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: Pro Week 6 Pd(n= 0,1)	50.00 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: GHS Scale	Global Health: C33D1(n= 0,16)	67.19 Units on a scale	Standard Deviation 27.3

Secondary

EORTC QLQ-C30 Questionnaire Score: Symptom Subscale

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C2D1(n= 342, 369)	11.50 Units on a scale	Standard Deviation 19.3
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C3D1(n= 253, 305)	7.05 Units on a scale	Standard Deviation 15.06
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C4D1(n= 223, 279)	7.40 Units on a scale	Standard Deviation 14.37
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C5D1(n= 167, 238)	6.29 Units on a scale	Standard Deviation 12.49
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C6D1(n= 151, 225)	6.40 Units on a scale	Standard Deviation 13.17
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C7D1(n= 88, 190)	6.82 Units on a scale	Standard Deviation 13.28
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C8D1(n= 72, 170)	6.02 Units on a scale	Standard Deviation 12.91
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C9D1(n= 50, 153)	3.33 Units on a scale	Standard Deviation 8.91
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C10D1(n= 47, 146)	2.48 Units on a scale	Standard Deviation 6.93
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C11D1(n= 37, 134)	3.15 Units on a scale	Standard Deviation 6.62
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C12D1(n= 30, 132)	3.89 Units on a scale	Standard Deviation 8.4
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C13D1(n= 19, 124)	4.39 Units on a scale	Standard Deviation 9.37
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C14D1(n= 18, 121)	4.63 Units on a scale	Standard Deviation 9.58
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C15D1(n= 16, 113)	1.04 Units on a scale	Standard Deviation 4.17
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C16D1(n= 13, 109)	5.13 Units on a scale	Standard Deviation 10.51
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C17D1(n= 11, 98)	9.09 Units on a scale	Standard Deviation 13.67
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C18D1(n= 10, 92)	6.67 Units on a scale	Standard Deviation 11.65
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C19D1(n= 9, 84)	3.70 Units on a scale	Standard Deviation 7.35
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C20D1(n= 9, 80)	5.56 Units on a scale	Standard Deviation 8.33
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C21D1(n= 9, 75)	1.85 Units on a scale	Standard Deviation 5.56
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C22D1(n= 8, 69)	6.25 Units on a scale	Standard Deviation 8.63
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C23D1(n= 8, 66)	6.25 Units on a scale	Standard Deviation 12.4
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C24D1(n= 5, 64)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C25D1(n= 3, 60)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C26D1(n= 3, 55)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C27D1(n= 3, 52)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C28D1(n= 1, 49)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C29D1(n= 2, 40)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: Baseline (n= 389, 413)	8.01 Units on a scale	Standard Deviation 16.34
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: EOT(n= 266, 245)	11.65 Units on a scale	Standard Deviation 20.11
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: Survival FU 1 (n= 2, 1)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: Baseline (n= 390, 413)	29.70 Units on a scale	Standard Deviation 29.45
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C2D1(n= 343, 368)	28.43 Units on a scale	Standard Deviation 27.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C3D1(n= 256, 305)	22.59 Units on a scale	Standard Deviation 24.93
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C4D1(n= 224, 280)	21.65 Units on a scale	Standard Deviation 24.48
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C5D1(n= 167, 239)	20.96 Units on a scale	Standard Deviation 22.55
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C6D1(n= 151, 225)	22.41 Units on a scale	Standard Deviation 21.95
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C7D1(n= 88, 190)	21.59 Units on a scale	Standard Deviation 22.34
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C8D1(n= 72, 171)	23.38 Units on a scale	Standard Deviation 22.49
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C9D1(n= 50, 153)	16.33 Units on a scale	Standard Deviation 20.89
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C10D1(n= 47, 146)	14.54 Units on a scale	Standard Deviation 17.93
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C11D1(n= 37, 134)	13.96 Units on a scale	Standard Deviation 22.05
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C12D1(n= 30, 132)	13.33 Units on a scale	Standard Deviation 21.17
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C13D1(n= 19, 124)	16.67 Units on a scale	Standard Deviation 25.46
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C14D1(n= 18, 120)	12.04 Units on a scale	Standard Deviation 15.97
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C15D1(n= 16, 113)	10.42 Units on a scale	Standard Deviation 17.08
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C16D1(n= 13, 109)	21.79 Units on a scale	Standard Deviation 21.93
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C17D1(n= 11, 98)	16.67 Units on a scale	Standard Deviation 19.72
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C18D1(n= 10, 92)	11.67 Units on a scale	Standard Deviation 22.29
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C19D1(n= 9, 84)	14.81 Units on a scale	Standard Deviation 22.74
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C20D1(n=9, 80)	27.78 Units on a scale	Standard Deviation 31.18
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C21D1(n= 9, 75)	14.81 Units on a scale	Standard Deviation 17.57
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C22D1(n= 8, 69)	18.75 Units on a scale	Standard Deviation 20.77
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C23D1(n= 8, 66)	14.58 Units on a scale	Standard Deviation 27.37
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C24D1(n=5, 64)	30.00 Units on a scale	Standard Deviation 36.13
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C25D1(n= 3, 60)	16.67 Units on a scale	Standard Deviation 28.87
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C26D1(n= 3, 55)	22.22 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C27D1(n= 3, 52)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C28D1(n= 1, 49)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C29D1(n= 2, 40)	41.67 Units on a scale	Standard Deviation 58.93
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: EOT (n= 267, 247)	32.21 Units on a scale	Standard Deviation 30.36
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: Survival FU-1 (n= 2,1)	66.67 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: Baseline (n= 390, 413)	37.59 Units on a scale	Standard Deviation 25.69
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C2D1(n= 343, 369)	40.52 Units on a scale	Standard Deviation 25.68
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C3D1(n= 256, 304)	35.29 Units on a scale	Standard Deviation 23.97
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C4D1(n= 224, 278)	35.59 Units on a scale	Standard Deviation 23.1
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C5D1(n= 167, 238)	36.03 Units on a scale	Standard Deviation 22.4
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C6D1(n= 151, 225)	36.28 Units on a scale	Standard Deviation 23.4
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C7D1(n= 88, 190)	34.34 Units on a scale	Standard Deviation 23.02
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C8D1(n= 72, 170)	30.86 Units on a scale	Standard Deviation 24.12
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C9D1(n= 50, 153)	28.67 Units on a scale	Standard Deviation 23.45
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C10D1(n= 47, 145)	29.31 Units on a scale	Standard Deviation 25.21
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C11D1(n= 37, 134)	27.63 Units on a scale	Standard Deviation 25.07
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C12D1(n= 30, 132)	28.89 Units on a scale	Standard Deviation 23.99
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C13D1(n= 19, 124)	22.22 Units on a scale	Standard Deviation 20.29
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C14D1(n= 18, 121)	21.60 Units on a scale	Standard Deviation 16.82
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C15D1(n= 16, 112)	20.14 Units on a scale	Standard Deviation 18.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C16D1(n= 13, 109)	21.79 Units on a scale	Standard Deviation 17.64
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C17D1(n= 11, 98)	22.22 Units on a scale	Standard Deviation 12.17
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C18D1(n= 10, 92)	26.67 Units on a scale	Standard Deviation 17.53
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C19D1(n= 9, 84)	22.22 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C20D1(n= 9, 80)	32.10 Units on a scale	Standard Deviation 30.15
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C21D1(n= 9, 75)	28.39 Units on a scale	Standard Deviation 18.52
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C22D1(n= 8, 69)	33.33 Units on a scale	Standard Deviation 29.1
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C23D1(n= 8, 66)	25.00 Units on a scale	Standard Deviation 24.31
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C24D1(n= 5, 64)	31.11 Units on a scale	Standard Deviation 40.37
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C25D1(n= 3, 60)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C26D1(n= 3, 55)	18.52 Units on a scale	Standard Deviation 16.97
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C27D1(n= 3, 52)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C28D1(n= 1, 49)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C29D1(n= 2, 40)	44.44 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C30D1(n= 1, 31)	22.22 Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: EOT(n= 267, 246)	47.50 Units on a scale	Standard Deviation 26.72
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: Pro Week 6 Pd(n= 0, 1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: Survival FU-1 (n= 2, 1)	83.33 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C21D1(n= 9, 75)	19.78 Units on a scale	Standard Deviation 25.95
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: Baseline (n= 389, 413)	7.59 Units on a scale	Standard Deviation 16.35
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C26D1(n= 3, 55)	28.69 Units on a scale	Standard Deviation 24.54
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C2D1(n= 342, 369)	9.53 Units on a scale	Standard Deviation 17.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C22D1(n= 8, 69)	15.22 Units on a scale	Standard Deviation 19.75
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C3D1(n= 253, 305)	7.27 Units on a scale	Standard Deviation 15.32
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C11D1(n= 37, 134)	25.62 Units on a scale	Standard Deviation 23.05
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C4D1(n= 223, 279)	7.17 Units on a scale	Standard Deviation 15.5
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C23D1(n= 8, 66)	16.92 Units on a scale	Standard Deviation 23.11
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C5D1(n= 167, 238)	6.44 Units on a scale	Standard Deviation 14.54
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C34D1(n= 0, 14)	31.75 Units on a scale	Standard Deviation 24.21
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C6D1(n= 151, 225)	6.44 Units on a scale	Standard Deviation 15.16
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C24D1(n=5, 64)	20.05 Units on a scale	Standard Deviation 25.05
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C7D1(n= 88, 190)	5.61 Units on a scale	Standard Deviation 13.74
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C12D1(n= 30, 132)	26.60 Units on a scale	Standard Deviation 23.37
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C8D1(n= 72, 170)	4.61 Units on a scale	Standard Deviation 10.57
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C25D1(n= 3, 60)	18.33 Units on a scale	Standard Deviation 22.9
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C9D1(n= 50, 153)	2.83 Units on a scale	Standard Deviation 8.06
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C27D1(n= 3, 52)	22.65 Units on a scale	Standard Deviation 19.8
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C10D1(n= 47, 146)	3.54 Units on a scale	Standard Deviation 10.02
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C26D1(n= 3, 55)	16.36 Units on a scale	Standard Deviation 21.87
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C11D1(n= 37, 134)	3.23 Units on a scale	Standard Deviation 8.54
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C13D1(n= 19, 124)	27.51 Units on a scale	Standard Deviation 22.73
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C12D1(n= 30, 132)	3.03 Units on a scale	Standard Deviation 7.66
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C27D1(n= 3, 52)	15.06 Units on a scale	Standard Deviation 20.41
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C13D1(n= 19, 124)	3.36 Units on a scale	Standard Deviation 10.19
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C35D1(n= 0, 12)	25.00 Units on a scale	Standard Deviation 21.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C14D1(n= 18, 121)	3.31 Units on a scale	Standard Deviation 9.03
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C28D1(n= 1, 49)	14.29 Units on a scale	Standard Deviation 18.63
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C15D1(n= 16, 113)	3.83 Units on a scale	Standard Deviation 11.14
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C14D1(n= 18, 121)	26.31 Units on a scale	Standard Deviation 23.13
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C16D1(n= 13, 109)	2.75 Units on a scale	Standard Deviation 8.64
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C29D1(n= 2, 40)	13.75 Units on a scale	Standard Deviation 18.06
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C17D1(n= 11, 98)	2.55 Units on a scale	Standard Deviation 8.06
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C28D1(n= 1, 49)	22.34 Units on a scale	Standard Deviation 18.23
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C18D1(n= 10, 92)	3.08 Units on a scale	Standard Deviation 8.88
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C30D1(n= 1, 31)	15.05 Units on a scale	Standard Deviation 21.24
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C19D1(n= 9, 84)	4.17 Units on a scale	Standard Deviation 11.53
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C15D1(n= 16, 112)	27.73 Units on a scale	Standard Deviation 22.56
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C20D1(n= 9, 80)	3.13 Units on a scale	Standard Deviation 11.28
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C31D1(n= 0, 24)	14.58 Units on a scale	Standard Deviation 21.03
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C21D1(n= 9, 75)	4.89 Units on a scale	Standard Deviation 13.08
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: Pro Week 6 Pd(n= 0, 1)	44.44 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C22D1(n= 8, 69)	1.93 Units on a scale	Standard Deviation 7.31
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C32D1(n= 0, 22)	16.67 Units on a scale	Standard Deviation 24.67
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C23D1(n= 8, 66)	2.53 Units on a scale	Standard Deviation 6.69
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C16D1(n= 13, 109)	27.22 Units on a scale	Standard Deviation 23.35
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C24D1(n= 5, 64)	2.34 Units on a scale	Standard Deviation 7.19
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C33D1(n= 0, 16)	20.83 Units on a scale	Standard Deviation 27.55
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C25D1(n= 3, 60)	1.94 Units on a scale	Standard Deviation 6.21
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C29D1(n= 2, 40)	21.11 Units on a scale	Standard Deviation 18.63
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C26D1(n= 3, 55)	2.73 Units on a scale	Standard Deviation 8.34
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C34D1(n= 0, 14)	26.19 Units on a scale	Standard Deviation 27.51
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C27D1(n= 3, 52)	2.24 Units on a scale	Standard Deviation 6.62
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C17D1(n= 11, 98)	27.21 Units on a scale	Standard Deviation 23.56
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C28D1(n= 1, 49)	1.02 Units on a scale	Standard Deviation 4.04
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C35D1(n= 0, 12)	22.22 Units on a scale	Standard Deviation 25.95
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C29D1(n= 2, 40)	1.67 Units on a scale	Standard Deviation 5.06
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C36D1(n= 0, 8)	16.67 Units on a scale	Standard Deviation 15.71
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C30D1(n= 1, 31)	1.61 Units on a scale	Standard Deviation 5.01
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C36D1(n= 0, 8)	22.92 Units on a scale	Standard Deviation 34.43
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C31D1(n= 0, 24)	2.08 Units on a scale	Standard Deviation 5.63
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C18D1(n= 10, 92)	27.29 Units on a scale	Standard Deviation 24.18
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C32D1(n= 0, 22)	1.52 Units on a scale	Standard Deviation 4.9
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C37D1(n= 0, 5)	30.00 Units on a scale	Standard Deviation 34.16
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C33D1(n= 0,16)	1.04 Units on a scale	Standard Deviation 4.17
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C30D1(n= 1, 31)	23.66 Units on a scale	Standard Deviation 20.23
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C34D1(n= 0, 14)	2.38 Units on a scale	Standard Deviation 8.91
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C35D1(n= 0, 12)	1.39 Units on a scale	Standard Deviation 4.81
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C19D1(n= 9, 84)	27.65 Units on a scale	Standard Deviation 22.85
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: EOT (n= 267, 247)	35.43 Units on a scale	Standard Deviation 31.22
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C37D1(n= 0, 5)	6.67 Units on a scale	Standard Deviation 9.13
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: EOT(n= 267, 246)	43.07 Units on a scale	Standard Deviation 28.15
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: Pro Week 6 Pd(n= 0,1)	16.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: EOT(n= 266, 245)	10.61 Units on a scale	Standard Deviation 17.62
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C20D1(n= 9, 80)	25.21 Units on a scale	Standard Deviation 23.47
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: Pro Week 6 Pd(n= 0,1)	16.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: Survival FU-1 (n= 2,1)	83.33 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Nausea/Vomiting: Survival FU 1 (n= 2, 1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C31D1(n= 0, 24)	23.15 Units on a scale	Standard Deviation 20.96
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: Baseline (n= 390, 413)	29.98 Units on a scale	Standard Deviation 29.72
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: Baseline (n= 390, 413)	36.21 Units on a scale	Standard Deviation 23.92
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C2D1(n= 343, 368)	29.30 Units on a scale	Standard Deviation 29.03
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C21D1(n= 9, 75)	26.44 Units on a scale	Standard Deviation 23.66
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C3D1(n= 256, 305)	24.15 Units on a scale	Standard Deviation 27.5
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C2D1(n= 343, 369)	39.78 Units on a scale	Standard Deviation 26.17
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C4D1(n= 224, 280)	23.75 Units on a scale	Standard Deviation 25.84
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C37D1(n= 0, 5)	24.44 Units on a scale	Standard Deviation 16.48
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C5D1(n= 167, 239)	23.22 Units on a scale	Standard Deviation 25.41
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C3D1(n= 256, 304)	33.90 Units on a scale	Standard Deviation 23.75
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C6D1(n= 151, 225)	21.63 Units on a scale	Standard Deviation 24.68
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C22D1(n= 8, 69)	22.38 Units on a scale	Standard Deviation 21.77
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C7D1(n= 88, 190)	21.58 Units on a scale	Standard Deviation 25.3
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C4D1(n= 224, 278)	30.72 Units on a scale	Standard Deviation 22.57
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C8D1(n= 72, 171)	22.03 Units on a scale	Standard Deviation 24.36
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C32D1(n= 0, 22)	25.25 Units on a scale	Standard Deviation 20.63
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C9D1(n= 50, 153)	19.28 Units on a scale	Standard Deviation 23.5
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C23D1(n= 8, 66)	24.16 Units on a scale	Standard Deviation 20.59
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C10D1(n= 47, 146)	21.00 Units on a scale	Standard Deviation 24.61
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C5D1(n= 167, 238)	30.95 Units on a scale	Standard Deviation 24.13
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C11D1(n= 37, 134)	21.27 Units on a scale	Standard Deviation 26.6
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: Survival FU-1 (n= 2, 1)	88.89 Units on a scale	—
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C12D1(n= 30, 132)	18.69 Units on a scale	Standard Deviation 24.71
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C6D1(n= 151, 225)	28.89 Units on a scale	Standard Deviation 22.66
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C13D1(n= 19, 124)	17.74 Units on a scale	Standard Deviation 21.23
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C24D1(n= 5, 64)	23.78 Units on a scale	Standard Deviation 18.87
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C14D1(n= 18, 120)	17.64 Units on a scale	Standard Deviation 22.17
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C7D1(n= 88, 190)	28.33 Units on a scale	Standard Deviation 22.15
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C15D1(n= 16, 113)	17.40 Units on a scale	Standard Deviation 22.86
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C33D1(n= 0, 16)	29.86 Units on a scale	Standard Deviation 26.52
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C16D1(n= 13, 109)	20.64 Units on a scale	Standard Deviation 25.25
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C8D1(n= 72, 170)	27.97 Units on a scale	Standard Deviation 21.56
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C17D1(n= 11, 98)	20.41 Units on a scale	Standard Deviation 25.39
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C25D1(n= 3, 60)	23.89 Units on a scale	Standard Deviation 20.94
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C18D1(n= 10, 92)	20.83 Units on a scale	Standard Deviation 24.54
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C9D1(n= 50, 153)	25.78 Units on a scale	Standard Deviation 21.39
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C19D1(n= 9, 84)	22.42 Units on a scale	Standard Deviation 28.16
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C38D1(n= 0, 2)	16.67 Units on a scale	Standard Deviation 7.86
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Pain: C20D1(n=9, 80)	20.00 Units on a scale	Standard Deviation 23.78
Atezolizumab	EORTC QLQ-C30 Questionnaire Score: Symptom Subscale	Fatigue: C10D1(n= 47, 145)	26.32 Units on a scale	Standard Deviation 22.27

Secondary

EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items

EORTC QLQ-C30 included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C15D1(n= 15, 113)	2.22 Units on a scale	Standard Deviation 8.61
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: EOT(n= 265, 246)	10.57 Units on a scale	Standard Deviation 19.18
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: Pro Week 6 Pd(n= 0, 1)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: Survival FU-1 (n= 2, 1)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: Baseline (n=387, 411)	20.76 Units on a scale	Standard Deviation 27.61
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C2D1 (n=336, 362)	18.45 Units on a scale	Standard Deviation 26.2
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C3D1 (n=253, 305)	16.86 Units on a scale	Standard Deviation 24.24
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C4D1 (n=219, 280)	16.74 Units on a scale	Standard Deviation 23.97
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C5D1 (n=165, 238)	16.57 Units on a scale	Standard Deviation 24.03
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C6D1 (n=149, 224)	15.66 Units on a scale	Standard Deviation 24.06
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C7D1 (n=86, 189)	16.28 Units on a scale	Standard Deviation 24.92
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C8D1 (n=71, 170)	13.15 Units on a scale	Standard Deviation 21.44
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C9D1 (n=49, 152)	16.33 Units on a scale	Standard Deviation 28.16
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C10D1 (n=46, 146)	14.49 Units on a scale	Standard Deviation 23.99
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C11D1 (n=36, 134)	9.26 Units on a scale	Standard Deviation 21.98
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C12D1 (n=30, 132)	12.22 Units on a scale	Standard Deviation 23.95
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C13D1 (n=18, 122)	12.96 Units on a scale	Standard Deviation 25.92
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C14D1 (n=17, 121)	15.69 Units on a scale	Standard Deviation 26.66
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C15D1 (n=15, 113)	6.67 Units on a scale	Standard Deviation 18.69
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C16D1 (n=12, 109)	13.89 Units on a scale	Standard Deviation 30.01
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C17D1 (n=11, 98)	15.15 Units on a scale	Standard Deviation 22.92
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C18D1 (n=10, 92)	10.00 Units on a scale	Standard Deviation 22.5
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C19D1 (n=9, 84)	3.70 Units on a scale	Standard Deviation 11.11
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C20D1 (n=9, 80)	11.11 Units on a scale	Standard Deviation 33.33
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C21D1 (n=9, 75)	11.11 Units on a scale	Standard Deviation 33.33
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C22D1 (n=8, 68)	12.50 Units on a scale	Standard Deviation 35.36
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C23D1 (n=7, 66)	9.52 Units on a scale	Standard Deviation 25.2
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C24D1 (n=5, 64)	13.33 Units on a scale	Standard Deviation 29.81
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C25D1 (n=3, 60)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C26D1 (n=3, 55)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C27D1 (n=3, 52)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C28D1 (n=1, 48)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C29D1 (n=2, 40)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C30D1 (n=1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C31D1(n=0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C32D1(n=0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C33D1(n=0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C34D1(n=0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C35D1(n=0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C36D1(n=0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C37D1(n=0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C38D1(n=0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: EOT(n=263, 245)	21.80 Units on a scale	Standard Deviation 29.23
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: Pro Week 6 Pd (n=0, 1)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties:Survival FU-1 (n=2,24)	83.33 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: Baseline (n= 388, 413)	28.87 Units on a scale	Standard Deviation 30.55
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C2D1(n= 340, 367)	27.55 Units on a scale	Standard Deviation 30.87
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C3D1(n= 253, 304)	25.69 Units on a scale	Standard Deviation 29.15
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C4D1(n= 222, 279)	21.32 Units on a scale	Standard Deviation 26.07
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C5D1(n= 166, 237)	21.49 Units on a scale	Standard Deviation 25.43
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C6D1(n= 150, 225)	22.00 Units on a scale	Standard Deviation 26.71
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C7D1(n= 87, 189)	21.07 Units on a scale	Standard Deviation 25.47
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C8D1(n= 70, 169)	15.24 Units on a scale	Standard Deviation 23.87
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C9D1(n= 49, 153)	16.33 Units on a scale	Standard Deviation 26.46
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C10D1(n= 46, 144)	13.77 Units on a scale	Standard Deviation 19.34
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C11D1(n= 36, 133)	9.26 Units on a scale	Standard Deviation 18.87
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C12D1(n= 29, 132)	16.09 Units on a scale	Standard Deviation 30.37
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C13D1(n= 17, 124)	17.65 Units on a scale	Standard Deviation 29.15
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C14D1(n= 17, 121)	25.49 Units on a scale	Standard Deviation 27.71
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C15D1(n= 15, 113)	22.22 Units on a scale	Standard Deviation 29.99
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C16D1(n= 13, 108)	20.51 Units on a scale	Standard Deviation 25.6
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C17D1(n= 11, 98)	21.21 Units on a scale	Standard Deviation 26.97
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C18D1(n= 10, 92)	20.00 Units on a scale	Standard Deviation 32.2
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C19D1(n= 9, 83)	18.52 Units on a scale	Standard Deviation 24.22
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C20D1(n= 9, 80)	18.52 Units on a scale	Standard Deviation 33.79
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C21D1(n= 9, 75)	22.22 Units on a scale	Standard Deviation 33.33
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C22D1(n= 8, 69)	16.67 Units on a scale	Standard Deviation 35.63
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C23D1(n= 8, 66)	20.83 Units on a scale	Standard Deviation 35.36
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C24D1(n= 5, 64)	26.67 Units on a scale	Standard Deviation 27.89
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C25D1(n= 3, 60)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C26D1(n= 3, 55)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C27D1(n= 3, 52)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C28D1(n= 1, 49)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C29D1(n= 2, 40)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: EOT(n= 264, 246)	28.91 Units on a scale	Standard Deviation 30.65
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: Pro Week Pd(n= 0, 1)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: Survival FU-1 (n= 2, 1)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C1D1 (n= 389, 412)	33.50 Units on a scale	Standard Deviation 31.11
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C2D1 (n= 341, 368)	32.55 Units on a scale	Standard Deviation 29.03
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C3D1 (n= 255, 302)	29.93 Units on a scale	Standard Deviation 27.54
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C4D1 (n= 389, 277)	28.38 Units on a scale	Standard Deviation 24.37
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C5D1 (n= 222, 236)	29.52 Units on a scale	Standard Deviation 24.46
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C6D1 (n= 166, 222)	30.02 Units on a scale	Standard Deviation 26.32
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C7D1 (n= 151, 188)	27.13 Units on a scale	Standard Deviation 25.31
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C8D1 (n= 86, 169)	28.70 Units on a scale	Standard Deviation 29.76
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C9D1 (n= 72, 152)	26.67 Units on a scale	Standard Deviation 28.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C10D1 (n= 50, 146)	27.66 Units on a scale	Standard Deviation 28.93
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C11D1 (n= 47, 134)	25.23 Units on a scale	Standard Deviation 30.84
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C12D1 (n= 37, 132)	26.67 Units on a scale	Standard Deviation 26.84
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C13D1 (n= 30, 123)	19.30 Units on a scale	Standard Deviation 23.08
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C14D1 (n= 19, 119)	20.37 Units on a scale	Standard Deviation 25.92
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C15D1 (n= 16, 113)	16.67 Units on a scale	Standard Deviation 17.21
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C16D1 (n= 13, 109)	20.51 Units on a scale	Standard Deviation 16.88
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C17D1 (n= 11, 98)	15.15 Units on a scale	Standard Deviation 17.41
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C18D1 (n= 10, 92)	20.00 Units on a scale	Standard Deviation 17.21
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C19D1 (n= 9, 84)	11.11 Units on a scale	Standard Deviation 16.67
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C20D1 (n= 9, 80)	18.52 Units on a scale	Standard Deviation 17.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C21D1 (n= 9, 75)	18.52 Units on a scale	Standard Deviation 17.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C22D1 (n= 8, 68)	20.83 Units on a scale	Standard Deviation 35.36
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C23D1 (n= 8, 65)	12.50 Units on a scale	Standard Deviation 17.25
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C24D1 (n= 5, 64)	6.67 Units on a scale	Standard Deviation 14.91
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C25D1 (n= 3, 60)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C26D1 (n= 3, 55)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C27D1 (n= 3, 52)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C28D1 (n= 1, 49)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C29D1 (n= 2, 40)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C30D1 (n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C31D1 (n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C32D1 (n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C33D1 (n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C34D1 (n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C35D1 (n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C36D1 (n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C37D1 (n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C38D1 (n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: EOT(n= 266, 247)	38.72 Units on a scale	Standard Deviation 30.51
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: Pro Week 6 Pd (n= 0, 1)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: Survival Follow-Up 1 (n= 2, 1)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: Baseline (n= 390, 413)	26.58 Units on a scale	Standard Deviation 31.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: Cycle (C) 2 Day (D) 1(n= 342, 368)	27.49 Units on a scale	Standard Deviation 30.39
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C3D1(n= 256, 304)	21.35 Units on a scale	Standard Deviation 28.84
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C4D1(n= 224, 279)	18.75 Units on a scale	Standard Deviation 25.36
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C5D1(n= 166, 238)	18.88 Units on a scale	Standard Deviation 23.89
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C6D1(n= 151, 224)	18.98 Units on a scale	Standard Deviation 25.68
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C7D1(n= 88, 190)	15.91 Units on a scale	Standard Deviation 24.75
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C8D1(n= 72, 170)	13.89 Units on a scale	Standard Deviation 22.2
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C9D1(n= 50, 153)	8.00 Units on a scale	Standard Deviation 18.52
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C10D1(n= 47, 146)	7.80 Units on a scale	Standard Deviation 15.87
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C11D1(n= 37, 134)	11.71 Units on a scale	Standard Deviation 23.85
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C12D1(n= 30, 132)	11.11 Units on a scale	Standard Deviation 20.22
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C24D1(n= 5, 64)	13.33 Units on a scale	Standard Deviation 18.26
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C13D1(n= 19, 123)	10.53 Units on a scale	Standard Deviation 15.92
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C14D1(n= 18, 120)	7.41 Units on a scale	Standard Deviation 14.26
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C15D1(n= 16, 113)	6.25 Units on a scale	Standard Deviation 13.44
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C16D1(n= 13, 109)	7.69 Units on a scale	Standard Deviation 14.62
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C17D1(n= 11, 98)	6.06 Units on a scale	Standard Deviation 13.48
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C18D1(n= 10, 91)	6.67 Units on a scale	Standard Deviation 14.05
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C19D1(n= 9, 84)	7.41 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C20D1(n= 9, 80)	11.11 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C21D1(n= 9, 75)	3.70 Units on a scale	Standard Deviation 11.11
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C22D1(n= 8, 69)	8.33 Units on a scale	Standard Deviation 15.43
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C23D1(n= 8, 66)	8.33 Units on a scale	Standard Deviation 15.43
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C25D1(n= 3, 60)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C26D1(n= 3, 55)	22.22 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C27D1(n= 3, 52)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C28D1(n= 1, 49)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C29D1(n= 2, 40)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: End of treatment (EOT)(n= 265, 246)	29.81 Units on a scale	Standard Deviation 31.85
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: Survival Follow-up (FU) 1 (n= 2, 1)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: Baseline (n= 388, 410)	19.93 Units on a scale	Standard Deviation 27.39
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C2D1(n= 339, 363)	19.47 Units on a scale	Standard Deviation 26.42
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C3D1(n= 255, 304)	19.74 Units on a scale	Standard Deviation 26.91
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C4D1(n= 224, 277)	17.86 Units on a scale	Standard Deviation 23.38
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C5D1(n= 166, 236)	13.05 Units on a scale	Standard Deviation 21.33
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C6D1(n= 151, 225)	14.35 Units on a scale	Standard Deviation 23.89
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C7D1(n= 87, 188)	13.41 Units on a scale	Standard Deviation 20.62
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C8D1(n= 72, 171)	8.33 Units on a scale	Standard Deviation 15.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C9D1(n= 50, 153)	9.33 Units on a scale	Standard Deviation 19.1
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C10D1(n= 47, 146)	9.22 Units on a scale	Standard Deviation 17.99
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C11D1(n= 37, 134)	5.41 Units on a scale	Standard Deviation 12.46
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C12D1(n= 30, 132)	11.11 Units on a scale	Standard Deviation 20.22
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C13D1(n= 19, 124)	5.26 Units on a scale	Standard Deviation 12.49
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C14D1(n= 17, 121)	15.69 Units on a scale	Standard Deviation 23.91
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C16D1(n= 13, 109)	20.51 Units on a scale	Standard Deviation 32.03
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C17D1(n= 11, 98)	12.12 Units on a scale	Standard Deviation 22.47
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C18D1(n= 10, 92)	6.67 Units on a scale	Standard Deviation 14.05
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C19D1(n= 9, 83)	7.41 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C20D1(n=9, 80)	14.81 Units on a scale	Standard Deviation 33.79
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C21D1(n= 9, 75)	7.41 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C22D1(n= 8, 69)	12.50 Units on a scale	Standard Deviation 24.8
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C23D1(n= 8, 66)	4.17 Units on a scale	Standard Deviation 11.78
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C24D1(n=5, 65)	20.00 Units on a scale	Standard Deviation 29.81
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C25D1(n= 3, 60)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C26D1(n= 2, 55)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C27D1(n= 3, 52)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C28D1(n= 1, 48)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C29D1(n= 2, 40)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C35D1(n= 0, 12)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: EOT (n= 265, 246)	19.12 Units on a scale	Standard Deviation 27.28
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: Survival FU-1 (n= 2,1)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: Baseline (n= 388, 411)	5.84 Units on a scale	Standard Deviation 13.77
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C2D1(n= 339, 361)	11.21 Units on a scale	Standard Deviation 20.65
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C3D1(n= 255, 304)	10.07 Units on a scale	Standard Deviation 18.68
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C4D1(n= 223, 280)	8.22 Units on a scale	Standard Deviation 16.35
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C5D1(n= 166, 238)	8.43 Units on a scale	Standard Deviation 17.48
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C6D1(n= 151, 222)	7.51 Units on a scale	Standard Deviation 14.99
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C7D1(n= 87, 189)	10.34 Units on a scale	Standard Deviation 17.1
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C8D1(n= 72, 171)	7.41 Units on a scale	Standard Deviation 15.03
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C9D1(n= 50, 153)	11.33 Units on a scale	Standard Deviation 17.31
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C10D1(n= 47, 146)	7.80 Units on a scale	Standard Deviation 14.27
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C11D1(n= 36, 134)	8.33 Units on a scale	Standard Deviation 14.64
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C12D1(n= 30, 132)	10.00 Units on a scale	Standard Deviation 17.83
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C13D1(n= 18, 124)	11.11 Units on a scale	Standard Deviation 16.17
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C14D1(n= 17, 121)	3.92 Units on a scale	Standard Deviation 11.07
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C15D1(n= 15, 113)	8.89 Units on a scale	Standard Deviation 15.26
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C16D1(n= 12, 108)	13.89 Units on a scale	Standard Deviation 17.16
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C17D1(n= 11, 98)	9.09 Units on a scale	Standard Deviation 15.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C18D1(n= 10, 92)	13.33 Units on a scale	Standard Deviation 17.21
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C19D1(n= 9, 84)	14.81 Units on a scale	Standard Deviation 17.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C20D1(n= 9, 80)	7.41 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C21D1(n= 9, 75)	18.52 Units on a scale	Standard Deviation 17.57
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C22D1(n= 8, 68)	16.67 Units on a scale	Standard Deviation 25.2
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C23D1(n= 8, 66)	8.33 Units on a scale	Standard Deviation 15.43
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C24D1(n= 5, 64)	6.67 Units on a scale	Standard Deviation 14.91
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C25D1(n= 3, 60)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C26D1(n= 3, 55)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C27D1(n= 3, 52)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C28D1(n= 1, 48)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C29D1(n= 2, 40)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C35D1(n= 0, 12)	NA Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C35D1 (n= 0, 12)	25.00 Units on a scale	Standard Deviation 25.13
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C15D1(n= 15, 113)	10.03 Units on a scale	Standard Deviation 17.75
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C36D1 (n= 0, 8)	20.83 Units on a scale	Standard Deviation 17.25
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C37D1(n= 0, 5)	6.67 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C27D1(n= 3, 52)	5.77 Units on a scale	Standard Deviation 15.79
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C37D1 (n= 0, 5)	26.67 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: EOT(n= 265, 246)	9.35 Units on a scale	Standard Deviation 20.39
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C16D1(n= 13, 109)	9.79 Units on a scale	Standard Deviation 18.87
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: Pro Week 6 Pd(n= 0, 1)	0.00 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C38D1 (n= 0, 2)	33.33 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: Survival FU-1 (n= 2, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C5D1(n= 166, 238)	6.58 Units on a scale	Standard Deviation 16.16
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: Baseline (n=387, 411)	18.09 Units on a scale	Standard Deviation 28.32
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: EOT(n= 266, 247)	39.41 Units on a scale	Standard Deviation 32.57
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C2D1 (n=336, 362)	15.93 Units on a scale	Standard Deviation 26.28
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C17D1(n= 11, 98)	9.86 Units on a scale	Standard Deviation 19.27
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C3D1 (n=253, 305)	15.63 Units on a scale	Standard Deviation 25.79
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: Pro Week 6 Pd (n= 0, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C4D1 (n=219, 280)	15.12 Units on a scale	Standard Deviation 24.72
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C20D1(n= 9, 80)	6.67 Units on a scale	Standard Deviation 14.43
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C5D1 (n=165, 238)	15.13 Units on a scale	Standard Deviation 25.71
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: Survival Follow-Up 1 (n= 2, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C6D1 (n=149, 224)	16.67 Units on a scale	Standard Deviation 26.41
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C18D1(n= 10, 92)	9.06 Units on a scale	Standard Deviation 17.89
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C7D1 (n=86, 189)	17.46 Units on a scale	Standard Deviation 27.41
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: Baseline (n= 390, 413)	22.92 Units on a scale	Standard Deviation 29.41
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C8D1 (n=71, 170)	18.82 Units on a scale	Standard Deviation 27.59
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C6D1(n= 151, 222)	6.31 Units on a scale	Standard Deviation 14.88
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C9D1 (n=49, 152)	17.54 Units on a scale	Standard Deviation 27.38
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: Cycle (C) 2 Day (D) 1(n= 342, 368)	26.99 Units on a scale	Standard Deviation 31.16
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C10D1 (n=46, 146)	17.81 Units on a scale	Standard Deviation 29.08
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C19D1(n= 9, 83)	9.64 Units on a scale	Standard Deviation 18.43
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C11D1 (n=36, 134)	19.65 Units on a scale	Standard Deviation 30.1
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C3D1(n= 256, 304)	21.16 Units on a scale	Standard Deviation 28.94
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C12D1 (n=30, 132)	18.43 Units on a scale	Standard Deviation 28.92
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C31D1(n= 0, 24)	6.94 Units on a scale	Standard Deviation 16.97
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C13D1 (n=18, 122)	18.31 Units on a scale	Standard Deviation 29.1
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C4D1(n= 224, 279)	18.40 Units on a scale	Standard Deviation 26.6
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C14D1 (n=17, 121)	18.46 Units on a scale	Standard Deviation 29.17
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C20D1(n=9, 80)	12.50 Units on a scale	Standard Deviation 23.35
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C15D1 (n=15, 113)	18.29 Units on a scale	Standard Deviation 28.86
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C5D1(n= 166, 238)	16.67 Units on a scale	Standard Deviation 27.52
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C16D1 (n=12, 109)	18.65 Units on a scale	Standard Deviation 29.2
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C7D1(n= 87, 189)	7.94 Units on a scale	Standard Deviation 17.24
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C17D1 (n=11, 98)	18.37 Units on a scale	Standard Deviation 27.55
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C6D1(n= 151, 224)	14.88 Units on a scale	Standard Deviation 25.39
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C18D1 (n=10, 92)	19.57 Units on a scale	Standard Deviation 28.45
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C21D1(n= 9, 75)	14.22 Units on a scale	Standard Deviation 25.22
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C19D1 (n=9, 84)	19.05 Units on a scale	Standard Deviation 28.94
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C7D1(n= 88, 190)	12.46 Units on a scale	Standard Deviation 23.06
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C20D1 (n=9, 80)	18.75 Units on a scale	Standard Deviation 27.99
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C21D1(n= 9, 75)	11.11 Units on a scale	Standard Deviation 18.45
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C21D1 (n=9, 75)	23.11 Units on a scale	Standard Deviation 30.99
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C8D1(n= 72, 170)	12.94 Units on a scale	Standard Deviation 23.27
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C22D1 (n=8, 68)	18.63 Units on a scale	Standard Deviation 28.44
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C22D1(n= 8, 69)	11.59 Units on a scale	Standard Deviation 21.26
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C23D1 (n=7, 66)	21.72 Units on a scale	Standard Deviation 30.66
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C9D1(n= 50, 153)	11.33 Units on a scale	Standard Deviation 22.35
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C24D1 (n=5, 64)	20.83 Units on a scale	Standard Deviation 29.99
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C8D1(n= 72, 171)	8.77 Units on a scale	Standard Deviation 17.56
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C25D1 (n=3, 60)	21.67 Units on a scale	Standard Deviation 31.19
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C10D1(n= 47, 146)	12.33 Units on a scale	Standard Deviation 21.45
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C26D1 (n=3, 55)	20.00 Units on a scale	Standard Deviation 30.5
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C23D1(n= 8, 66)	10.10 Units on a scale	Standard Deviation 20.23
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C27D1 (n=3, 52)	17.31 Units on a scale	Standard Deviation 28.38
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C11D1(n= 37, 134)	11.44 Units on a scale	Standard Deviation 22.43
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C28D1 (n=1, 48)	18.06 Units on a scale	Standard Deviation 26.59
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C28D1(n= 1, 48)	4.86 Units on a scale	Standard Deviation 13.73
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C29D1 (n=2, 40)	19.17 Units on a scale	Standard Deviation 28.13
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C24D1(n=5, 65)	9.74 Units on a scale	Standard Deviation 17.4
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C30D1 (n=1, 31)	17.20 Units on a scale	Standard Deviation 25.63
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C12D1(n= 30, 132)	8.84 Units on a scale	Standard Deviation 18.81
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C31D1(n=0, 24)	20.83 Units on a scale	Standard Deviation 25.66
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C9D1(n= 50, 153)	7.63 Units on a scale	Standard Deviation 16.44
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C32D1(n=0, 22)	21.21 Units on a scale	Standard Deviation 26.32
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C13D1(n= 19, 123)	8.40 Units on a scale	Standard Deviation 15.74
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C33D1(n=0, 16)	22.92 Units on a scale	Standard Deviation 29.11
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C25D1(n= 3, 60)	11.11 Units on a scale	Standard Deviation 19.08
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C34D1(n=0, 14)	26.19 Units on a scale	Standard Deviation 35.03
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C14D1(n= 18, 120)	10.00 Units on a scale	Standard Deviation 17.61
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C35D1(n=0, 12)	27.78 Units on a scale	Standard Deviation 37.15
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C22D1(n= 8, 68)	7.84 Units on a scale	Standard Deviation 16.41
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C36D1(n=0, 8)	8.33 Units on a scale	Standard Deviation 15.43
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C15D1(n= 16, 113)	12.39 Units on a scale	Standard Deviation 22.8
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C37D1(n=0, 5)	26.67 Units on a scale	Standard Deviation 43.46
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C26D1(n= 2, 55)	12.12 Units on a scale	Standard Deviation 20.65
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: C38D1(n=0, 2)	16.67 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C16D1(n= 13, 109)	10.09 Units on a scale	Standard Deviation 19.51
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: EOT(n=263, 245)	19.46 Units on a scale	Standard Deviation 28.75
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C10D1(n= 47, 146)	5.48 Units on a scale	Standard Deviation 15.67
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties: Pro Week 6 Pd (n=0, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C17D1(n= 11, 98)	7.82 Units on a scale	Standard Deviation 18.41
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Financial Difficulties:Survival FU-1 (n=2,24)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C27D1(n= 3, 52)	13.46 Units on a scale	Standard Deviation 20.09
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: Baseline (n= 388, 413)	26.15 Units on a scale	Standard Deviation 28.72
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C18D1(n= 10, 91)	8.06 Units on a scale	Standard Deviation 18.15
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C12D1(n= 29, 132)	21.46 Units on a scale	Standard Deviation 24.41
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C2D1(n= 340, 367)	26.52 Units on a scale	Standard Deviation 28.61
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C33D1(n= 0, 16)	8.33 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C3D1(n= 253, 304)	24.89 Units on a scale	Standard Deviation 27.32
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C19D1(n= 9, 84)	9.13 Units on a scale	Standard Deviation 18.18
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C4D1(n= 222, 279)	23.66 Units on a scale	Standard Deviation 26.48
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C28D1(n= 1, 48)	11.81 Units on a scale	Standard Deviation 22.27
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C5D1(n= 166, 237)	25.88 Units on a scale	Standard Deviation 29.84
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C20D1(n= 9, 80)	9.58 Units on a scale	Standard Deviation 21.34
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C6D1(n= 150, 225)	23.41 Units on a scale	Standard Deviation 27.73
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C11D1(n= 36, 134)	4.98 Units on a scale	Standard Deviation 14.46
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C7D1(n= 87, 189)	23.99 Units on a scale	Standard Deviation 26.65
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C21D1(n= 9, 75)	12.44 Units on a scale	Standard Deviation 26.15
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C8D1(n= 70, 169)	23.87 Units on a scale	Standard Deviation 26.27
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C29D1(n= 2, 40)	15.83 Units on a scale	Standard Deviation 23.86
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C9D1(n= 49, 153)	22.88 Units on a scale	Standard Deviation 27.16
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C22D1(n= 8, 69)	6.76 Units on a scale	Standard Deviation 16.74
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C10D1(n= 46, 144)	21.53 Units on a scale	Standard Deviation 26.87
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C23D1(n= 8, 66)	6.06 Units on a scale	Standard Deviation 16.44
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C11D1(n= 36, 133)	20.55 Units on a scale	Standard Deviation 27.44
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C23D1(n= 8, 66)	7.58 Units on a scale	Standard Deviation 17.34
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C24D1(n= 5, 64)	8.33 Units on a scale	Standard Deviation 15.71
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C13D1(n= 17, 124)	23.39 Units on a scale	Standard Deviation 28.51
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C30D1(n= 1, 31)	8.60 Units on a scale	Standard Deviation 19.18
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C14D1(n= 17, 121)	23.69 Units on a scale	Standard Deviation 26.33
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C25D1(n= 3, 60)	6.11 Units on a scale	Standard Deviation 13.01
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C15D1(n= 15, 113)	21.53 Units on a scale	Standard Deviation 28.84
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C12D1(n= 30, 132)	6.31 Units on a scale	Standard Deviation 16.54
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C16D1(n= 13, 108)	21.60 Units on a scale	Standard Deviation 31.01
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C26D1(n= 3, 55)	5.45 Units on a scale	Standard Deviation 12.45
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C17D1(n= 11, 98)	20.07 Units on a scale	Standard Deviation 28.21
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C31D1(n= 0, 24)	9.72 Units on a scale	Standard Deviation 20.8
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C18D1(n= 10, 92)	21.38 Units on a scale	Standard Deviation 27.77
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C27D1(n= 3, 52)	9.62 Units on a scale	Standard Deviation 19.06
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C19D1(n= 9, 83)	22.49 Units on a scale	Standard Deviation 28.09
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C29D1(n= 2, 40)	9.17 Units on a scale	Standard Deviation 18.47
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C20D1(n= 9, 80)	20.83 Units on a scale	Standard Deviation 29.71
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C28D1(n= 1, 49)	7.48 Units on a scale	Standard Deviation 15.61
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C21D1(n= 9, 75)	20.89 Units on a scale	Standard Deviation 29.9
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C32D1(n= 0, 22)	6.06 Units on a scale	Standard Deviation 13.16
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C22D1(n= 8, 69)	18.84 Units on a scale	Standard Deviation 26.49
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C29D1(n= 2, 40)	9.17 Units on a scale	Standard Deviation 16.86
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C23D1(n= 8, 66)	19.70 Units on a scale	Standard Deviation 28.03
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C13D1(n= 18, 124)	5.65 Units on a scale	Standard Deviation 14.55
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C24D1(n= 5, 64)	19.79 Units on a scale	Standard Deviation 25
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C30D1(n= 1, 31)	1.08 Units on a scale	Standard Deviation 5.99
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C25D1(n= 3, 60)	18.89 Units on a scale	Standard Deviation 23.26
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C33D1(n= 0, 16)	4.17 Units on a scale	Standard Deviation 11.39
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C26D1(n= 3, 55)	21.21 Units on a scale	Standard Deviation 27.49
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C31D1(n= 0, 24)	6.94 Units on a scale	Standard Deviation 13.83
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C27D1(n= 3, 52)	19.23 Units on a scale	Standard Deviation 28.27
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C24D1(n= 5, 64)	6.25 Units on a scale	Standard Deviation 16.67
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C28D1(n= 1, 49)	21.09 Units on a scale	Standard Deviation 27.8
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C32D1(n= 0, 22)	7.58 Units on a scale	Standard Deviation 22.84
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C29D1(n= 2, 40)	21.67 Units on a scale	Standard Deviation 26.74
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C34D1(n= 0, 14)	7.14 Units on a scale	Standard Deviation 14.19
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C30D1(n= 1, 31)	20.43 Units on a scale	Standard Deviation 28.12
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C33D1(n= 0,16)	8.33 Units on a scale	Standard Deviation 25.82
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C31D1(n= 0, 24)	20.83 Units on a scale	Standard Deviation 27.47
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C14D1(n= 17, 121)	9.92 Units on a scale	Standard Deviation 19.07
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C32D1(n= 0, 22)	19.70 Units on a scale	Standard Deviation 26.55
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C34D1(n= 0, 14)	4.76 Units on a scale	Standard Deviation 17.82
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C33D1(n= 0, 16)	20.83 Units on a scale	Standard Deviation 34.16
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C35D1(n= 0, 12)	5.56 Units on a scale	Standard Deviation 12.97
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C34D1(n= 0, 14)	23.81 Units on a scale	Standard Deviation 24.21
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C35D1(n= 0, 12)	8.33 Units on a scale	Standard Deviation 20.72
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C35D1(n= 0, 12)	25.00 Units on a scale	Standard Deviation 28.87
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C32D1(n= 0, 22)	12.12 Units on a scale	Standard Deviation 16.41
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C36D1(n= 0, 8)	25.00 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C37D1(n= 0, 5)	33.33 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: C38D1(n= 0, 2)	16.67 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C37D1(n= 0, 5)	6.67 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: EOT(n= 264, 246)	29.95 Units on a scale	Standard Deviation 30.3
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C15D1(n= 15, 113)	7.96 Units on a scale	Standard Deviation 17.97
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: Pro Week Pd(n= 0, 1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Insomnia: Survival FU-1 (n= 2, 1)	100.00 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C37D1(n= 0, 5)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C1D1 (n= 389, 412)	32.04 Units on a scale	Standard Deviation 28.73
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: End of treatment (EOT)(n= 265, 246)	31.98 Units on a scale	Standard Deviation 33.51
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C2D1 (n= 341, 368)	31.88 Units on a scale	Standard Deviation 29.7
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C25D1(n= 3, 60)	6.11 Units on a scale	Standard Deviation 14.38
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C3D1 (n= 255, 302)	27.15 Units on a scale	Standard Deviation 26.73
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: Pro Week 6 Pd(n= 0,1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C4D1 (n= 389, 277)	28.28 Units on a scale	Standard Deviation 27.48
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C5D1 (n= 222, 236)	27.82 Units on a scale	Standard Deviation 27.03
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Appetite Loss: Survival Follow-up (FU) 1 (n= 2, 1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C6D1 (n= 166, 222)	26.88 Units on a scale	Standard Deviation 25.63
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C16D1(n= 12, 108)	6.48 Units on a scale	Standard Deviation 14.02
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C7D1 (n= 151, 188)	25.53 Units on a scale	Standard Deviation 25.99
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: Baseline (n= 388, 410)	16.50 Units on a scale	Standard Deviation 26.81
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C8D1 (n= 86, 169)	26.43 Units on a scale	Standard Deviation 26.7
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: EOT (n= 265, 246)	19.78 Units on a scale	Standard Deviation 28.36
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C9D1 (n= 72, 152)	24.12 Units on a scale	Standard Deviation 24.92
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C2D1(n= 339, 363)	18.09 Units on a scale	Standard Deviation 26.92
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C10D1 (n= 50, 146)	23.52 Units on a scale	Standard Deviation 23.54
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C30D1(n= 1, 31)	7.53 Units on a scale	Standard Deviation 16.58
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C11D1 (n= 47, 134)	22.89 Units on a scale	Standard Deviation 25
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C3D1(n= 255, 304)	15.13 Units on a scale	Standard Deviation 23.71
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C12D1 (n= 37, 132)	22.73 Units on a scale	Standard Deviation 25.83
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: Pro Week 6 Pd(n= 0,1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C13D1 (n= 30, 123)	25.47 Units on a scale	Standard Deviation 26.68
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C4D1(n= 224, 277)	14.56 Units on a scale	Standard Deviation 23.58
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C14D1 (n= 19, 119)	21.85 Units on a scale	Standard Deviation 25.47
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C17D1(n= 11, 98)	7.82 Units on a scale	Standard Deviation 16.44
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C15D1 (n= 16, 113)	22.71 Units on a scale	Standard Deviation 24.51
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C5D1(n= 166, 236)	12.15 Units on a scale	Standard Deviation 21.16
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C16D1 (n= 13, 109)	21.71 Units on a scale	Standard Deviation 25
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: Survival FU-1 (n= 2,1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C17D1 (n= 11, 98)	21.43 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C6D1(n= 151, 225)	12.89 Units on a scale	Standard Deviation 22.42
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C18D1 (n= 10, 92)	22.83 Units on a scale	Standard Deviation 25.64
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C26D1(n= 3, 55)	10.30 Units on a scale	Standard Deviation 21.15
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C19D1 (n= 9, 84)	23.41 Units on a scale	Standard Deviation 23.59
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C7D1(n= 87, 188)	11.52 Units on a scale	Standard Deviation 21.04
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C20D1 (n= 9, 80)	21.67 Units on a scale	Standard Deviation 24.36
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: Baseline (n= 388, 411)	7.22 Units on a scale	Standard Deviation 17.86
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C21D1 (n= 9, 75)	19.11 Units on a scale	Standard Deviation 20.63
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C8D1(n= 72, 171)	12.28 Units on a scale	Standard Deviation 21.36
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C22D1 (n= 8, 68)	20.59 Units on a scale	Standard Deviation 23.06
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C18D1(n= 10, 92)	8.70 Units on a scale	Standard Deviation 17.73
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C23D1 (n= 8, 65)	18.46 Units on a scale	Standard Deviation 21.27
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C9D1(n= 50, 153)	10.68 Units on a scale	Standard Deviation 17.79
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C24D1 (n= 5, 64)	19.79 Units on a scale	Standard Deviation 24.28
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C2D1(n= 339, 361)	7.29 Units on a scale	Standard Deviation 17.72
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C25D1 (n= 3, 60)	20.00 Units on a scale	Standard Deviation 22.3
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C10D1(n= 47, 146)	9.82 Units on a scale	Standard Deviation 17.58
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C26D1 (n= 3, 55)	20.00 Units on a scale	Standard Deviation 24.51
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C34D1(n= 0, 14)	4.76 Units on a scale	Standard Deviation 12.1
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C27D1 (n= 3, 52)	16.03 Units on a scale	Standard Deviation 19.23
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C11D1(n= 37, 134)	9.95 Units on a scale	Standard Deviation 17.83
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C28D1 (n= 1, 49)	17.01 Units on a scale	Standard Deviation 20.55
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C3D1(n= 255, 304)	6.14 Units on a scale	Standard Deviation 15.75
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C29D1 (n= 2, 40)	15.00 Units on a scale	Standard Deviation 21.28
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C12D1(n= 30, 132)	10.86 Units on a scale	Standard Deviation 18.65
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C30D1 (n= 1, 31)	16.13 Units on a scale	Standard Deviation 18.99
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C19D1(n= 9, 84)	7.94 Units on a scale	Standard Deviation 18.38
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C31D1 (n= 0, 24)	22.22 Units on a scale	Standard Deviation 23.4
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C13D1(n= 19, 124)	8.60 Units on a scale	Standard Deviation 15.83
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C32D1 (n= 0, 22)	22.73 Units on a scale	Standard Deviation 21.54
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C4D1(n= 223, 280)	6.67 Units on a scale	Standard Deviation 17.71
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C33D1 (n= 0, 16)	25.00 Units on a scale	Standard Deviation 31.03
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Constipation: C14D1(n= 17, 121)	9.09 Units on a scale	Standard Deviation 16.67
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Dyspnea: C34D1 (n= 0, 14)	26.19 Units on a scale	Standard Deviation 26.73
Atezolizumab	EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items	Diarrhea: C35D1(n= 0, 12)	5.56 Units on a scale	Standard Deviation 12.97

Secondary

EORTC QLQ-LC13 Questionnaire Score: Alopecia

QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for alopecia.

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C13D1(n= 19, 121)	42.11 Units on a scale	Standard Deviation 41.34
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C21D1(n= 9, 73)	22.22 Units on a scale	Standard Deviation 33.33
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C16D1(n= 12, 105)	27.78 Units on a scale	Standard Deviation 31.25
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C22D1(n= 7, 67)	9.52 Units on a scale	Standard Deviation 16.26
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C12D1(n= 29, 129)	36.78 Units on a scale	Standard Deviation 43.04
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C23D1(n= 8, 64)	29.17 Units on a scale	Standard Deviation 37.53
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C17D1(n= 11, 95)	21.21 Units on a scale	Standard Deviation 30.81
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C24D1(n= 5, 62)	13.33 Units on a scale	Standard Deviation 18.26
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C14D1(n= 18, 119)	29.63 Units on a scale	Standard Deviation 35.95
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: EOT(n= 261, 243)	53.51 Units on a scale	Standard Deviation 38.91
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C25D1(n= 2, 58)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C18D1(n= 9, 90)	22.22 Units on a scale	Standard Deviation 33.33
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: Survival FU 1 (n= 2, 1)	100.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C26D1(n= 2, 53)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: Baseline (n= 384, 405)	13.89 Units on a scale	Standard Deviation 27.95
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C11D1(n= 36, 130)	47.22 Units on a scale	Standard Deviation 45.34
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C2D1(n= 332, 357)	60.44 Units on a scale	Standard Deviation 36.66
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C27D1(n= 3, 50)	33.33 Units on a scale	Standard Deviation 57.74
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C3D1(n= 248, 300)	56.72 Units on a scale	Standard Deviation 35.86
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C19D1(n= 8, 81)	25.00 Units on a scale	Standard Deviation 34.5
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C4D1(n= 219, 270)	52.36 Units on a scale	Standard Deviation 35.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C28D1(n= 2, 46)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C5D1(n= 163, 234)	56.65 Units on a scale	Standard Deviation 37.25
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C15D1(n= 16, 110)	33.33 Units on a scale	Standard Deviation 34.43
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C6D1(n= 147, 220)	54.42 Units on a scale	Standard Deviation 37.64
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C29D1(n= 2, 38)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C7D1(n= 87, 186)	52.11 Units on a scale	Standard Deviation 39.28
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C20D1(n= 9, 78)	44.44 Units on a scale	Standard Deviation 44.1
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C8D1(n= 70, 166)	48.57 Units on a scale	Standard Deviation 37.94
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C9D1(n= 47, 150)	48.23 Units on a scale	Standard Deviation 39.81
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C10D1(n= 45, 142)	49.63 Units on a scale	Standard Deviation 39.96
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C9D1(n= 47, 150)	5.11 Units on a scale	Standard Deviation 14.83
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C10D1(n= 45, 142)	3.76 Units on a scale	Standard Deviation 13.23
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C11D1(n= 36, 130)	3.08 Units on a scale	Standard Deviation 11.33
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C12D1(n= 29, 129)	4.91 Units on a scale	Standard Deviation 13.88
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C13D1(n= 19, 121)	6.06 Units on a scale	Standard Deviation 15.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C14D1(n= 18, 119)	5.60 Units on a scale	Standard Deviation 14.6
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C15D1(n= 16, 110)	7.27 Units on a scale	Standard Deviation 17.12
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C16D1(n= 12, 105)	7.30 Units on a scale	Standard Deviation 17.89
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C17D1(n= 11, 95)	9.47 Units on a scale	Standard Deviation 19.85
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C18D1(n= 9, 90)	8.89 Units on a scale	Standard Deviation 17.16
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C19D1(n= 8, 81)	10.29 Units on a scale	Standard Deviation 18.74
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C20D1(n= 9, 78)	8.55 Units on a scale	Standard Deviation 15.6
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C21D1(n= 9, 73)	9.59 Units on a scale	Standard Deviation 16.18
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C22D1(n= 7, 67)	9.45 Units on a scale	Standard Deviation 16.21
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C23D1(n= 8, 64)	11.46 Units on a scale	Standard Deviation 18.99
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C24D1(n= 5, 62)	8.06 Units on a scale	Standard Deviation 15.61
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C25D1(n= 2, 58)	9.77 Units on a scale	Standard Deviation 16.53
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C26D1(n= 2, 53)	9.43 Units on a scale	Standard Deviation 16.51
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C27D1(n= 3, 50)	9.33 Units on a scale	Standard Deviation 16.55
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C28D1(n= 2, 46)	6.52 Units on a scale	Standard Deviation 15.1
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C29D1(n= 2, 38)	8.77 Units on a scale	Standard Deviation 20.04
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C30D1(n= 1, 31)	10.75 Units on a scale	Standard Deviation 19.98
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C31D1(n= 0, 24)	9.72 Units on a scale	Standard Deviation 20.8
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C32D1(n= 0, 23)	7.25 Units on a scale	Standard Deviation 19.99
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C33D1(n= 0,16)	8.33 Units on a scale	Standard Deviation 22.77
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C34D1(n= 0, 14)	9.52 Units on a scale	Standard Deviation 20.38
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C35D1(n= 0, 11)	6.06 Units on a scale	Standard Deviation 13.48
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C37D1(n= 0, 5)	6.67 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: EOT(n= 261, 243)	6.58 Units on a scale	Standard Deviation 17.48
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: Pro Week 6 Pd(n= 0,1)	100.00 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: Survival FU 1 (n= 2, 1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: Baseline (n= 384, 405)	14.32 Units on a scale	Standard Deviation 29.07
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C2D1(n= 332, 357)	6.63 Units on a scale	Standard Deviation 16.84
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C3D1(n= 248, 300)	7.44 Units on a scale	Standard Deviation 18.89
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C4D1(n= 219, 270)	7.41 Units on a scale	Standard Deviation 19.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C5D1(n= 163, 234)	6.41 Units on a scale	Standard Deviation 16.68
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C6D1(n= 147, 220)	7.88 Units on a scale	Standard Deviation 19.34
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C7D1(n= 87, 186)	5.91 Units on a scale	Standard Deviation 16.1
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Alopecia	Alopecia: C8D1(n= 70, 166)	6.63 Units on a scale	Standard Deviation 17.68

Secondary

EORTC QLQ-LC13 Questionnaire Score: Coughing

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C11D1(n= 37, 129)	21.62 Units on a scale	Standard Deviation 19.59
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C22D1(n= 8, 67)	25.00 Units on a scale	Standard Deviation 38.83
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C4D1(n= 219, 272)	31.35 Units on a scale	Standard Deviation 24.13
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C23D1(n= 8, 64)	20.83 Units on a scale	Standard Deviation 17.25
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C12D1(n= 30, 129)	20.00 Units on a scale	Standard Deviation 18.77
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C24D1(n= 5, 62)	26.67 Units on a scale	Standard Deviation 14.91
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C13D1(n= 19, 121)	15.79 Units on a scale	Standard Deviation 17.1
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C25D1(n= 3, 58)	33.33 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C7D1(n= 87, 185)	32.95 Units on a scale	Standard Deviation 24.64
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C26D1(n= 3, 53)	44.44 Units on a scale	Standard Deviation 19.25
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C14D1(n= 18, 119)	16.67 Units on a scale	Standard Deviation 17.15
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C27D1(n= 3, 50)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C3D1(n= 250, 298)	33.73 Units on a scale	Standard Deviation 27.46
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C28D1(n= 2, 46)	16.67 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C15D1(n= 16, 110)	12.50 Units on a scale	Standard Deviation 16.67
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C29D1(n= 2, 38)	16.67 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C8D1(n= 69, 166)	30.43 Units on a scale	Standard Deviation 28.43
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C16D1(n= 13, 106)	20.51 Units on a scale	Standard Deviation 21.68
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C5D1(n= 164, 235)	32.72 Units on a scale	Standard Deviation 23.49
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C17D1(n= 11, 94)	21.21 Units on a scale	Standard Deviation 16.82
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C9D1(n= 50, 150)	24.67 Units on a scale	Standard Deviation 17.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C18D1(n= 10, 90)	26.67 Units on a scale	Standard Deviation 21.08
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C2D1(n= 333, 360)	36.54 Units on a scale	Standard Deviation 28.04
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C19D1(n= 9, 82)	22.22 Units on a scale	Standard Deviation 16.67
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C10D1(n= 47, 140)	23.40 Units on a scale	Standard Deviation 19.55
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C20D1(n= 9, 78)	25.93 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: EOT(n= 262, 246)	35.75 Units on a scale	Standard Deviation 27.03
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C6D1(n= 147, 219)	31.75 Units on a scale	Standard Deviation 24.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C21D1(n= 9, 73)	22.22 Units on a scale	Standard Deviation 16.67
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: Survival FU 1 (n= 2, 1)	50.00 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: Baseline (n= 383, 406)	38.73 Units on a scale	Standard Deviation 29.64
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: Survival FU 1 (n= 2, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: Baseline (n= 383, 406)	37.27 Units on a scale	Standard Deviation 27.23
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C12D1(n= 30, 129)	25.06 Units on a scale	Standard Deviation 23.95
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C2D1(n= 333, 360)	37.50 Units on a scale	Standard Deviation 28.33
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C3D1(n= 250, 298)	33.89 Units on a scale	Standard Deviation 24.99
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C4D1(n= 219, 272)	32.48 Units on a scale	Standard Deviation 25.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C5D1(n= 164, 235)	31.35 Units on a scale	Standard Deviation 25.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C6D1(n= 147, 219)	31.05 Units on a scale	Standard Deviation 24.73
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C7D1(n= 87, 185)	30.99 Units on a scale	Standard Deviation 25.07
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C8D1(n= 69, 166)	29.12 Units on a scale	Standard Deviation 25.73
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C9D1(n= 50, 150)	29.11 Units on a scale	Standard Deviation 24.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C10D1(n= 47, 140)	27.86 Units on a scale	Standard Deviation 22.83
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C11D1(n= 37, 129)	27.39 Units on a scale	Standard Deviation 23.37
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C13D1(n= 19, 121)	24.79 Units on a scale	Standard Deviation 23.78
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C14D1(n= 18, 119)	24.37 Units on a scale	Standard Deviation 22.42
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C15D1(n= 16, 110)	25.76 Units on a scale	Standard Deviation 23.31
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C16D1(n= 13, 106)	24.53 Units on a scale	Standard Deviation 22.21
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C17D1(n= 11, 94)	24.82 Units on a scale	Standard Deviation 23.92
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C18D1(n= 10, 90)	26.30 Units on a scale	Standard Deviation 24.22
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C19D1(n= 9, 82)	25.61 Units on a scale	Standard Deviation 26.86
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C20D1(n= 9, 78)	28.21 Units on a scale	Standard Deviation 26.36
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C21D1(n= 9, 73)	28.77 Units on a scale	Standard Deviation 27.95
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C22D1(n= 8, 67)	22.89 Units on a scale	Standard Deviation 23.36
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C23D1(n= 8, 64)	23.44 Units on a scale	Standard Deviation 26.35
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C24D1(n= 5, 62)	24.73 Units on a scale	Standard Deviation 23.33
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C25D1(n= 3, 58)	25.86 Units on a scale	Standard Deviation 23.4
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C26D1(n= 3, 53)	26.41 Units on a scale	Standard Deviation 24.77
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C27D1(n= 3, 50)	24.67 Units on a scale	Standard Deviation 22.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C28D1(n= 2, 46)	20.29 Units on a scale	Standard Deviation 20.46
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C29D1(n= 2, 38)	19.30 Units on a scale	Standard Deviation 22.77
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C30D1(n= 1, 31)	18.28 Units on a scale	Standard Deviation 20.8
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C31D1(n= 0, 24)	23.61 Units on a scale	Standard Deviation 25.02
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C32D1(n= 0, 23)	26.09 Units on a scale	Standard Deviation 19.99
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C33D1(n= 0,16)	27.08 Units on a scale	Standard Deviation 32.7
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C34D1(n= 0, 14)	26.19 Units on a scale	Standard Deviation 29.75
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C35D1(n= 0, 11)	21.21 Units on a scale	Standard Deviation 22.47
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C36D1(n= 0, 8)	25.00 Units on a scale	Standard Deviation 15.43
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C37D1(n= 0, 5)	26.67 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: C38D1(n= 0, 2)	33.33 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: EOT(n= 262, 246)	38.48 Units on a scale	Standard Deviation 26.95
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Coughing	Coughing: Pro Week 6 Pd(n= 0,1)	33.33 Units on a scale	—

Secondary

EORTC QLQ-LC13 Questionnaire Score: Dysphagia

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C4D1(n= 217, 272)	8.60 Units on a scale	Standard Deviation 19.45
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C22D1(n= 8, 67)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C12D1(n= 29, 129)	2.30 Units on a scale	Standard Deviation 8.6
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C23D1(n= 8, 64)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C7D1(n= 87, 187)	4.21 Units on a scale	Standard Deviation 11.14
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C24D1(n= 5, 62)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C13D1(n= 19, 121)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C25D1(n= 3, 58)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C3D1(n= 251, 301)	9.16 Units on a scale	Standard Deviation 20.87
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C26D1(n= 3, 53)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C14D1(n= 18, 119)	5.56 Units on a scale	Standard Deviation 12.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C27D1(n= 3, 50)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C8D1(n=70, 167)	5.71 Units on a scale	Standard Deviation 12.65
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C28D1(n= 2, 46)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C15D1(n= 16, 110)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C29D1(n= 2, 38)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C5D1(n= 163, 236)	6.75 Units on a scale	Standard Deviation 16.63
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C16D1(n= 13, 106)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C9D1(n= 50, 151)	1.33 Units on a scale	Standard Deviation 6.6
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C17D1(n= 11, 95)	3.03 Units on a scale	Standard Deviation 10.05
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C2D1(n= 336, 358)	10.22 Units on a scale	Standard Deviation 21.5
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C18D1(n= 10, 90)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C10D1(n= 47, 143)	1.42 Units on a scale	Standard Deviation 6.8
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C19D1(n= 9, 82)	3.70 Units on a scale	Standard Deviation 11.11
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C6D1(n= 147, 219)	6.80 Units on a scale	Standard Deviation 15.58
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C20D1(n= 9, 78)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: EOT(n= 264, 245)	10.23 Units on a scale	Standard Deviation 20.77
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C11D1(n= 37, 130)	1.80 Units on a scale	Standard Deviation 7.64
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C21D1(n= 9, 73)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: Survival FU 1 (n= 2, 1)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: Baseline (n= 387, 406)	6.20 Units on a scale	Standard Deviation 17.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: Survival FU 1 (n= 2, 1)	0.00 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: Baseline (n= 387, 406)	5.09 Units on a scale	Standard Deviation 15.05
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C2D1(n= 336, 358)	6.42 Units on a scale	Standard Deviation 15.75
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C3D1(n= 251, 301)	5.43 Units on a scale	Standard Deviation 14.53
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C4D1(n= 217, 272)	5.88 Units on a scale	Standard Deviation 16.39
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C5D1(n= 163, 236)	6.64 Units on a scale	Standard Deviation 16.79
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C6D1(n= 147, 219)	4.72 Units on a scale	Standard Deviation 13.28
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C7D1(n= 87, 187)	5.70 Units on a scale	Standard Deviation 15.17
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C8D1(n=70, 167)	4.79 Units on a scale	Standard Deviation 12.82
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C9D1(n= 50, 151)	4.64 Units on a scale	Standard Deviation 14.42
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C10D1(n= 47, 143)	5.36 Units on a scale	Standard Deviation 15.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C11D1(n= 37, 130)	2.82 Units on a scale	Standard Deviation 11.01
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C12D1(n= 29, 129)	3.88 Units on a scale	Standard Deviation 12.93
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C13D1(n= 19, 121)	3.86 Units on a scale	Standard Deviation 11.54
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C14D1(n= 18, 119)	5.04 Units on a scale	Standard Deviation 13.47
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C15D1(n= 16, 110)	3.33 Units on a scale	Standard Deviation 11.01
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C16D1(n= 13, 106)	3.77 Units on a scale	Standard Deviation 12.45
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C17D1(n= 11, 95)	3.86 Units on a scale	Standard Deviation 13.63
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C18D1(n= 10, 90)	4.44 Units on a scale	Standard Deviation 15.96
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C19D1(n= 9, 82)	5.28 Units on a scale	Standard Deviation 15.24
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C20D1(n= 9, 78)	4.70 Units on a scale	Standard Deviation 12.85
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C21D1(n= 9, 73)	5.02 Units on a scale	Standard Deviation 15.39
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C22D1(n= 8, 67)	2.99 Units on a scale	Standard Deviation 11.21
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C23D1(n= 8, 64)	3.65 Units on a scale	Standard Deviation 12.05
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C24D1(n= 5, 62)	4.84 Units on a scale	Standard Deviation 15.79
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C25D1(n= 3, 58)	4.02 Units on a scale	Standard Deviation 15.39
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C26D1(n= 3, 53)	4.40 Units on a scale	Standard Deviation 13.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C27D1(n= 3, 50)	2.67 Units on a scale	Standard Deviation 11.35
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C28D1(n= 2, 46)	4.35 Units on a scale	Standard Deviation 15.09
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C29D1(n= 2, 38)	4.39 Units on a scale	Standard Deviation 13.8
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C30D1(n= 1, 31)	5.38 Units on a scale	Standard Deviation 15.15
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C31D1(n= 0, 24)	5.56 Units on a scale	Standard Deviation 21.23
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C32D1(n= 0, 23)	7.25 Units on a scale	Standard Deviation 17.28
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C33D1(n= 0,16)	6.25 Units on a scale	Standard Deviation 13.44
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C34D1(n= 0, 14)	9.52 Units on a scale	Standard Deviation 20.38
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C35D1(n= 0, 11)	3.03 Units on a scale	Standard Deviation 10.05
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C37D1(n= 0, 5)	6.67 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: EOT(n= 264, 245)	8.98 Units on a scale	Standard Deviation 18.87
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dysphagia	Dysphagia: Pro Week 6 Pd(n= 0,1)	0.00 Units on a scale	—

Secondary

EORTC QLQ-LC13 Questionnaire Score: Dyspnea

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C4D1(n= 220, 273)	27.75 Units on a scale	Standard Deviation 19.85
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C22D1(n= 8, 67)	18.06 Units on a scale	Standard Deviation 20.52
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C12D1(n= 30, 129)	22.41 Units on a scale	Standard Deviation 18.94
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C23D1(n= 8, 64)	16.67 Units on a scale	Standard Deviation 13.28
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C7D1(n= 87, 187)	25.35 Units on a scale	Standard Deviation 21.07
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C24D1(n= 5, 62)	20.00 Units on a scale	Standard Deviation 14.49
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C13D1(n= 19, 121)	16.37 Units on a scale	Standard Deviation 15.87
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C25D1(n= 3, 58)	29.63 Units on a scale	Standard Deviation 25.66
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C3D1(n= 252, 301)	28.13 Units on a scale	Standard Deviation 22.45
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C26D1(n= 3, 53)	22.22 Units on a scale	Standard Deviation 11.11
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C14D1(n= 18, 119)	17.90 Units on a scale	Standard Deviation 12.13
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C27D1(n= 3, 50)	18.52 Units on a scale	Standard Deviation 6.41
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C8D1(n=70, 167)	28.02 Units on a scale	Standard Deviation 24.12
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C28D1(n= 2, 46)	5.56 Units on a scale	Standard Deviation 7.86
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C15D1(n= 16, 110)	15.28 Units on a scale	Standard Deviation 12.75
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C29D1(n= 2, 38)	5.56 Units on a scale	Standard Deviation 7.86
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C5D1(n= 165, 236)	26.57 Units on a scale	Standard Deviation 19.61
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C30D1(n= 1, 31)	11.11 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C16D1(n= 13, 106)	14.53 Units on a scale	Standard Deviation 13.13
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C9D1(n= 50, 151)	26.00 Units on a scale	Standard Deviation 21.49
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C17D1(n= 10, 95)	18.89 Units on a scale	Standard Deviation 14.86
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C2D1(n= 335, 361)	28.14 Units on a scale	Standard Deviation 23.48
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C18D1(n= 10, 90)	20.00 Units on a scale	Standard Deviation 12.61
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C10D1(n= 47, 143)	27.42 Units on a scale	Standard Deviation 22.56
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C19D1(n= 9, 82)	18.52 Units on a scale	Standard Deviation 13.61
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C6D1(n= 148, 221)	29.69 Units on a scale	Standard Deviation 21.94
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C20D1(n= 9, 78)	20.37 Units on a scale	Standard Deviation 15.21
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: EOT(n= 263, 246)	36.12 Units on a scale	Standard Deviation 24.82
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C11D1(n= 37, 130)	22.67 Units on a scale	Standard Deviation 19.79
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C21D1(n= 9, 73)	19.75 Units on a scale	Standard Deviation 15.49
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: Survival FU 1 (n= 2, 1)	66.67 Units on a scale	Standard Deviation 15.71
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: Baseline (n= 386, 407)	28.55 Units on a scale	Standard Deviation 23.21
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: Survival FU 1 (n= 2, 1)	44.44 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: Baseline (n= 386, 407)	26.78 Units on a scale	Standard Deviation 22.43
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C2D1(n= 335, 361)	28.79 Units on a scale	Standard Deviation 23.67
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C3D1(n= 252, 301)	25.40 Units on a scale	Standard Deviation 20.6
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C4D1(n= 220, 273)	25.17 Units on a scale	Standard Deviation 21.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C5D1(n= 165, 236)	24.72 Units on a scale	Standard Deviation 19.9
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C6D1(n= 148, 221)	24.01 Units on a scale	Standard Deviation 21.09
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C7D1(n= 87, 187)	24.42 Units on a scale	Standard Deviation 21.23
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C8D1(n=70, 167)	24.42 Units on a scale	Standard Deviation 22.33
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C9D1(n= 50, 151)	22.44 Units on a scale	Standard Deviation 21.87
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C10D1(n= 47, 143)	22.18 Units on a scale	Standard Deviation 21.35
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C11D1(n= 37, 130)	20.43 Units on a scale	Standard Deviation 21.44
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C12D1(n= 30, 129)	22.27 Units on a scale	Standard Deviation 20.47
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C13D1(n= 19, 121)	22.22 Units on a scale	Standard Deviation 21.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C14D1(n= 18, 119)	22.41 Units on a scale	Standard Deviation 20.66
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C15D1(n= 16, 110)	22.12 Units on a scale	Standard Deviation 18.71
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C16D1(n= 13, 106)	21.91 Units on a scale	Standard Deviation 20.71
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C17D1(n= 10, 95)	23.51 Units on a scale	Standard Deviation 21.84
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C18D1(n= 10, 90)	22.65 Units on a scale	Standard Deviation 21.97
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C19D1(n= 9, 82)	22.09 Units on a scale	Standard Deviation 20.91
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C20D1(n= 9, 78)	22.65 Units on a scale	Standard Deviation 21.37
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C21D1(n= 9, 73)	20.40 Units on a scale	Standard Deviation 19.69
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C22D1(n= 8, 67)	19.90 Units on a scale	Standard Deviation 17.68
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C23D1(n= 8, 64)	21.2 Units on a scale	Standard Deviation 19.13
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C24D1(n= 5, 62)	21.33 Units on a scale	Standard Deviation 20.94
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C25D1(n= 3, 58)	19.73 Units on a scale	Standard Deviation 18.39
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C26D1(n= 3, 53)	21.80 Units on a scale	Standard Deviation 19.97
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C27D1(n= 3, 50)	20.33 Units on a scale	Standard Deviation 20.87
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C28D1(n= 2, 46)	18.36 Units on a scale	Standard Deviation 17.87
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C29D1(n= 2, 38)	19.30 Units on a scale	Standard Deviation 16.48
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C30D1(n= 1, 31)	17.92 Units on a scale	Standard Deviation 17.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C31D1(n= 0, 24)	24.07 Units on a scale	Standard Deviation 18.73
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C32D1(n= 0, 23)	24.15 Units on a scale	Standard Deviation 20
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C33D1(n= 0,16)	25.69 Units on a scale	Standard Deviation 27.13
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C34D1(n= 0, 14)	27.78 Units on a scale	Standard Deviation 22.96
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C35D1(n= 0, 11)	26.26 Units on a scale	Standard Deviation 19.42
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C36D1(n= 0, 8)	18.06 Units on a scale	Standard Deviation 13.2
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C37D1(n= 0, 5)	24.44 Units on a scale	Standard Deviation 4.97
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: C38D1(n= 0, 2)	16.67 Units on a scale	Standard Deviation 7.86
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: EOT(n= 263, 246)	34.51 Units on a scale	Standard Deviation 26.36
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Dyspnea	Dyspnea: Pro Week 6 Pd(n= 0,1)	22.22 Units on a scale	—

Secondary

EORTC QLQ-LC13 Questionnaire Score: Hemoptysis

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C4D1(n= 220, 270)	2.88 Units on a scale	Standard Deviation 10.89
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C22D1(n= 8, 67)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C12D1(n= 30, 129)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C23D1(n= 8, 64)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C7D1(n= 87, 187)	1.15 Units on a scale	Standard Deviation 6.12
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C24D1(n= 5, 61)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C13D1(n= 19, 121)	3.51 Units on a scale	Standard Deviation 10.51
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C25D1(n= 3, 58)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C3D1(n= 251, 301)	4.38 Units on a scale	Standard Deviation 13.11
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C26D1(n= 3, 53)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C14D1(n= 18, 119)	1.85 Units on a scale	Standard Deviation 7.86
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C27D1(n= 3, 50)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C8D1(n=70, 166)	1.90 Units on a scale	Standard Deviation 9.64
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C28D1(n= 2, 46)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C15D1(n= 16, 110)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C29D1(n= 2, 38)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C5D1(n= 163, 234)	1.43 Units on a scale	Standard Deviation 7.72
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C16D1(n= 13, 106)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C9D1(n= 50, 151)	2.00 Units on a scale	Standard Deviation 8
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C17D1(n= 11, 94)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C33D1(n= 0,16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C2D1(n= 336, 359)	4.76 Units on a scale	Standard Deviation 14.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C18D1(n= 10, 90)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C10D1(n= 47, 143)	2.84 Units on a scale	Standard Deviation 9.4
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C19D1(n= 9, 82)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C6D1(n= 148, 219)	1.80 Units on a scale	Standard Deviation 7.56
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C20D1(n= 9, 78)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: EOT(n= 264, 243)	5.18 Units on a scale	Standard Deviation 14.33
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C11D1(n= 37, 130)	1.80 Units on a scale	Standard Deviation 7.64
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C21D1(n= 8, 73)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: Survival FU 1 (n= 2, 1)	33.33 Units on a scale	Standard Deviation 47.14
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: Baseline (n= 386, 406)	4.32 Units on a scale	Standard Deviation 13.32
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: Survival FU 1 (n= 2, 1)	0.00 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: Baseline (n= 386, 406)	3.86 Units on a scale	Standard Deviation 12.12
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C2D1(n= 336, 359)	3.16 Units on a scale	Standard Deviation 10.97
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C3D1(n= 251, 301)	3.10 Units on a scale	Standard Deviation 11.12
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C4D1(n= 220, 270)	2.10 Units on a scale	Standard Deviation 9.94
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C5D1(n= 163, 234)	1.42 Units on a scale	Standard Deviation 6.76
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C6D1(n= 148, 219)	1.22 Units on a scale	Standard Deviation 6.27
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C7D1(n= 87, 187)	1.43 Units on a scale	Standard Deviation 6.76
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C8D1(n=70, 166)	2.41 Units on a scale	Standard Deviation 10.09
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C9D1(n= 50, 151)	1.77 Units on a scale	Standard Deviation 7.49
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C10D1(n= 47, 143)	0.70 Units on a scale	Standard Deviation 4.79
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C11D1(n= 37, 130)	1.03 Units on a scale	Standard Deviation 5.78
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C12D1(n= 30, 129)	1.03 Units on a scale	Standard Deviation 5.8
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C13D1(n= 19, 121)	1.10 Units on a scale	Standard Deviation 5.98
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C14D1(n= 18, 119)	1.68 Units on a scale	Standard Deviation 7.32
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C15D1(n= 16, 110)	1.82 Units on a scale	Standard Deviation 10.91
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C16D1(n= 13, 106)	2.83 Units on a scale	Standard Deviation 10.41
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C17D1(n= 11, 94)	2.84 Units on a scale	Standard Deviation 12.61
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C18D1(n= 10, 90)	2.96 Units on a scale	Standard Deviation 12.88
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C19D1(n= 9, 82)	2.03 Units on a scale	Standard Deviation 12.11
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C20D1(n= 9, 78)	2.56 Units on a scale	Standard Deviation 12.9
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C21D1(n= 8, 73)	1.83 Units on a scale	Standard Deviation 7.64
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C22D1(n= 8, 67)	1.99 Units on a scale	Standard Deviation 9.85
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C23D1(n= 8, 64)	1.04 Units on a scale	Standard Deviation 5.85
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C24D1(n= 5, 61)	2.73 Units on a scale	Standard Deviation 11.05
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C25D1(n= 3, 58)	3.45 Units on a scale	Standard Deviation 13.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C26D1(n= 3, 53)	3.77 Units on a scale	Standard Deviation 14.11
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C27D1(n= 3, 50)	2.00 Units on a scale	Standard Deviation 8
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C28D1(n= 2, 46)	1.45 Units on a scale	Standard Deviation 6.87
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C29D1(n= 2, 38)	0.88 Units on a scale	Standard Deviation 5.41
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C30D1(n= 1, 31)	1.08 Units on a scale	Standard Deviation 5.99
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C31D1(n= 0, 24)	2.78 Units on a scale	Standard Deviation 9.41
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C32D1(n= 0, 23)	2.90 Units on a scale	Standard Deviation 9.6
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C33D1(n= 0,16)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C34D1(n= 0, 14)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C35D1(n= 0, 11)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C37D1(n= 0, 5)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: EOT(n= 264, 243)	6.04 Units on a scale	Standard Deviation 16.6
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Hemoptysis	Hemoptysis: Pro Week 6 Pd(n= 0,1)	0.00 Units on a scale	—

Secondary

EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder

Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days)

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C11D1(n= 36, 127)	11.11 Units on a scale	Standard Deviation 19.52
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C2D1(n= 332, 358)	19.58 Units on a scale	Standard Deviation 27.45
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C3D1(n= 248, 294)	17.20 Units on a scale	Standard Deviation 27.16
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C4D1(n= 217, 270)	14.75 Units on a scale	Standard Deviation 23.74
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C5D1(n= 164, 232)	16.06 Units on a scale	Standard Deviation 24.06
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C6D1(n= 147, 219)	15.42 Units on a scale	Standard Deviation 23.17
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C7D1(n= 86, 184)	14.73 Units on a scale	Standard Deviation 23.77
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C8D1(n=69, 163)	15.94 Units on a scale	Standard Deviation 25.95
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C9D1(n= 50, 149)	14.00 Units on a scale	Standard Deviation 24.36
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C10D1(n= 46, 141)	14.49 Units on a scale	Standard Deviation 20.67
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: Baseline (n= 384, 405)	20.49 Units on a scale	Standard Deviation 28.85
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C12D1(n= 30, 126)	12.22 Units on a scale	Standard Deviation 18.54
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C13D1(n= 19, 117)	12.28 Units on a scale	Standard Deviation 19.91
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C14D1(n= 18, 117)	11.11 Units on a scale	Standard Deviation 19.8
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C15D1(n= 16, 108)	12.50 Units on a scale	Standard Deviation 20.64
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C16D1(n= 13, 104)	7.69 Units on a scale	Standard Deviation 14.62
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C17D1(n= 11, 93)	9.09 Units on a scale	Standard Deviation 15.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C18D1(n= 10, 88)	13.33 Units on a scale	Standard Deviation 23.31
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C19D1(n= 9, 80)	7.41 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C20D1(n= 9, 76)	11.11 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C21D1(n= 9, 71)	11.11 Units on a scale	Standard Deviation 16.67
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C22D1(n= 8, 65)	16.67 Units on a scale	Standard Deviation 25.2
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C23D1(n= 8, 62)	16.67 Units on a scale	Standard Deviation 25.2
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C24D1(n= 5, 59)	20.00 Units on a scale	Standard Deviation 29.81
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C25D1(n= 3, 57)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C26D1(n= 2, 52)	16.67 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C27D1(n= 3, 49)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C28D1(n= 2, 45)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C29D1(n= 2, 37)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C30D1(n= 1, 30)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C31D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C32D1(n= 0, 22)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C33D1(n= 0, 15)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: EOT(n= 264, 242)	21.72 Units on a scale	Standard Deviation 30.48
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: Survival FU 1 (n= 2, 1)	83.33 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C31D1(n= 0, 23)	10.14 Units on a scale	Standard Deviation 21.17
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: Baseline (n= 384, 405)	20.16 Units on a scale	Standard Deviation 27.09
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C21D1(n= 9, 71)	12.68 Units on a scale	Standard Deviation 19.81
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C2D1(n= 332, 358)	18.34 Units on a scale	Standard Deviation 26.56
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C37D1(n= 0, 5)	33.33 Units on a scale	Standard Deviation 47.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C3D1(n= 248, 294)	16.44 Units on a scale	Standard Deviation 25.5
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C22D1(n= 8, 65)	13.33 Units on a scale	Standard Deviation 21.89
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C4D1(n= 217, 270)	18.15 Units on a scale	Standard Deviation 26.57
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C32D1(n= 0, 22)	13.64 Units on a scale	Standard Deviation 26.55
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C5D1(n= 164, 232)	14.94 Units on a scale	Standard Deviation 23.76
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C23D1(n= 8, 62)	15.05 Units on a scale	Standard Deviation 22.32
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C6D1(n= 147, 219)	15.68 Units on a scale	Standard Deviation 24.37
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: Survival FU 1 (n= 2, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C7D1(n= 86, 184)	16.67 Units on a scale	Standard Deviation 26.31
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C24D1(n= 5, 59)	18.08 Units on a scale	Standard Deviation 24.23
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C8D1(n=69, 163)	16.77 Units on a scale	Standard Deviation 25.22
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C33D1(n= 0, 15)	20.00 Units on a scale	Standard Deviation 27.6
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C9D1(n= 50, 149)	16.78 Units on a scale	Standard Deviation 25.89
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C25D1(n= 3, 57)	14.62 Units on a scale	Standard Deviation 21.84
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C10D1(n= 46, 141)	17.73 Units on a scale	Standard Deviation 27.18
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C34D1(n= 0, 14)	16.67 Units on a scale	Standard Deviation 28.49
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C11D1(n= 36, 127)	15.49 Units on a scale	Standard Deviation 26.82
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C26D1(n= 2, 52)	15.38 Units on a scale	Standard Deviation 22.35
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C12D1(n= 30, 126)	16.93 Units on a scale	Standard Deviation 26.91
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C13D1(n= 19, 117)	14.81 Units on a scale	Standard Deviation 22.93
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C27D1(n= 3, 49)	14.97 Units on a scale	Standard Deviation 23.63
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C14D1(n= 18, 117)	15.67 Units on a scale	Standard Deviation 22.56
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C35D1(n= 0, 11)	27.27 Units on a scale	Standard Deviation 32.72
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C15D1(n= 16, 108)	15.74 Units on a scale	Standard Deviation 24.31
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C28D1(n= 2, 45)	11.85 Units on a scale	Standard Deviation 19.01
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C16D1(n= 13, 104)	14.10 Units on a scale	Standard Deviation 23.54
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: Pro Week 6 Pd(n= 0,1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C17D1(n= 11, 93)	16.49 Units on a scale	Standard Deviation 25.83
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C29D1(n= 2, 37)	10.81 Units on a scale	Standard Deviation 22.3
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C36D1(n= 0, 8)	16.67 Units on a scale	Standard Deviation 35.63
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C18D1(n= 10, 88)	18.18 Units on a scale	Standard Deviation 25.73
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C30D1(n= 1, 30)	10.00 Units on a scale	Standard Deviation 21.71
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C19D1(n= 9, 80)	20.83 Units on a scale	Standard Deviation 29.23
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: EOT(n= 264, 242)	23.14 Units on a scale	Standard Deviation 29.55
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder	Pain in Arm or Shoulder: C20D1(n= 9, 76)	18.42 Units on a scale	Standard Deviation 25.18

Secondary

EORTC QLQ-LC13 Questionnaire Score: Pain in Chest

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C4D1(n= 217, 268)	14.44 Units on a scale	Standard Deviation 22.37
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C22D1(n= 8, 66)	4.17 Units on a scale	Standard Deviation 11.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C12D1(n= 30, 128)	3.33 Units on a scale	Standard Deviation 10.17
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C23D1(n= 8, 62)	4.17 Units on a scale	Standard Deviation 11.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C7D1(n= 86, 184)	12.40 Units on a scale	Standard Deviation 19.83
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C24D1(n= 5, 61)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C13D1(n= 19, 120)	3.51 Units on a scale	Standard Deviation 10.51
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C25D1(n= 3, 57)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C3D1(n= 249, 296)	14.59 Units on a scale	Standard Deviation 21.92
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C26D1(n= 2, 52)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C14D1(n= 18, 118)	5.56 Units on a scale	Standard Deviation 12.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C27D1(n= 3, 49)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C8D1(n=69, 164)	10.63 Units on a scale	Standard Deviation 20.21
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C28D1(n= 2, 45)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C15D1(n= 16, 109)	6.25 Units on a scale	Standard Deviation 13.44
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C29D1(n= 2, 37)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C5D1(n= 164, 233)	11.99 Units on a scale	Standard Deviation 18.42
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C16D1(n= 13, 105)	5.13 Units on a scale	Standard Deviation 12.52
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C9D1(n= 49, 149)	7.48 Units on a scale	Standard Deviation 17.03
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C17D1(n= 11, 94)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C2D1(n= 332, 356)	16.67 Units on a scale	Standard Deviation 24.65
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C18D1(n= 10, 89)	6.67 Units on a scale	Standard Deviation 14.05
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C10D1(n= 46, 142)	5.07 Units on a scale	Standard Deviation 12.11
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C19D1(n= 9, 80)	7.41 Units on a scale	Standard Deviation 14.7
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C6D1(n= 145, 217)	12.18 Units on a scale	Standard Deviation 19.96
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C20D1(n= 9, 76)	3.70 Units on a scale	Standard Deviation 11.11
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: EOT(n= 265, 245)	18.99 Units on a scale	Standard Deviation 26.35
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C11D1(n= 36, 127)	3.70 Units on a scale	Standard Deviation 10.62
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C21D1(n= 9, 71)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: Survival FU 1 (n= 2, 1)	50.00 Units on a scale	Standard Deviation 70.71
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: Baseline (n= 385, 403)	17.92 Units on a scale	Standard Deviation 25.33
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: Survival FU 1 (n= 2, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: Baseline (n= 385, 403)	19.52 Units on a scale	Standard Deviation 26.49
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C2D1(n= 332, 356)	15.26 Units on a scale	Standard Deviation 22.68
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C3D1(n= 249, 296)	15.43 Units on a scale	Standard Deviation 23.42
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C4D1(n= 217, 268)	14.43 Units on a scale	Standard Deviation 23.77
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C5D1(n= 164, 233)	12.16 Units on a scale	Standard Deviation 19.82
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C6D1(n= 145, 217)	12.60 Units on a scale	Standard Deviation 21.4
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C7D1(n= 86, 184)	11.78 Units on a scale	Standard Deviation 20.91
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C8D1(n=69, 164)	14.02 Units on a scale	Standard Deviation 21.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C9D1(n= 49, 149)	10.74 Units on a scale	Standard Deviation 20.96
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C10D1(n= 46, 142)	8.45 Units on a scale	Standard Deviation 19.62
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C11D1(n= 36, 127)	9.45 Units on a scale	Standard Deviation 22.18
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C12D1(n= 30, 128)	8.85 Units on a scale	Standard Deviation 17.49
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C13D1(n= 19, 120)	7.50 Units on a scale	Standard Deviation 16.99
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C14D1(n= 18, 118)	7.63 Units on a scale	Standard Deviation 15.96
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C15D1(n= 16, 109)	8.56 Units on a scale	Standard Deviation 18.37
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C16D1(n= 13, 105)	8.25 Units on a scale	Standard Deviation 16.53
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C17D1(n= 11, 94)	8.87 Units on a scale	Standard Deviation 20.84
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C18D1(n= 10, 89)	7.49 Units on a scale	Standard Deviation 15.69
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C19D1(n= 9, 80)	7.50 Units on a scale	Standard Deviation 19.1
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C20D1(n= 9, 76)	10.09 Units on a scale	Standard Deviation 20.38
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C21D1(n= 9, 71)	7.98 Units on a scale	Standard Deviation 15.39
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C22D1(n= 8, 66)	7.58 Units on a scale	Standard Deviation 16.33
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C23D1(n= 8, 62)	7.53 Units on a scale	Standard Deviation 17.51
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C24D1(n= 5, 61)	8.20 Units on a scale	Standard Deviation 15.7
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C25D1(n= 3, 57)	8.77 Units on a scale	Standard Deviation 16.09
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C26D1(n= 2, 52)	10.90 Units on a scale	Standard Deviation 19.49
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C27D1(n= 3, 49)	8.84 Units on a scale	Standard Deviation 18.97
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C28D1(n= 2, 45)	8.15 Units on a scale	Standard Deviation 16.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C29D1(n= 2, 37)	8.11 Units on a scale	Standard Deviation 16.49
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C30D1(n= 1, 31)	5.38 Units on a scale	Standard Deviation 12.46
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C31D1(n= 0, 24)	4.17 Units on a scale	Standard Deviation 11.26
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C32D1(n= 0, 23)	13.04 Units on a scale	Standard Deviation 19.43
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C33D1(n= 0, 16)	14.58 Units on a scale	Standard Deviation 24.25
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C34D1(n= 0, 14)	14.29 Units on a scale	Standard Deviation 25.2
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C35D1(n= 0, 11)	6.06 Units on a scale	Standard Deviation 13.48
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C37D1(n= 0, 5)	6.67 Units on a scale	Standard Deviation 14.91
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: EOT(n= 265, 245)	19.46 Units on a scale	Standard Deviation 26.95
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Chest	Pain in Chest: Pro Week 6 Pd(n= 0,1)	0.00 Units on a scale	—

Secondary

EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C4D1(n= 211, 263)	21.48 Units on a scale	Standard Deviation 26.86
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C22D1(n= 8, 62)	20.83 Units on a scale	Standard Deviation 24.8
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C12D1(n= 26, 122)	8.97 Units on a scale	Standard Deviation 17.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C23D1(n= 8, 62)	20.83 Units on a scale	Standard Deviation 30.54
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C7D1(n= 81, 180)	23.05 Units on a scale	Standard Deviation 28.21
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C24D1(n= 5, 61)	26.67 Units on a scale	Standard Deviation 43.46
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C13D1(n= 17, 113)	17.65 Units on a scale	Standard Deviation 23.91
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C25D1(n= 3, 55)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C3D1(n= 239, 286)	22.87 Units on a scale	Standard Deviation 27.79
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C26D1(n= 2, 50)	16.67 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C14D1(n= 18, 115)	18.52 Units on a scale	Standard Deviation 23.49
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C27D1(n= 3, 49)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C8D1(n=65, 158)	24.10 Units on a scale	Standard Deviation 28.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C28D1(n= 2, 44)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C15D1(n= 15, 106)	6.67 Units on a scale	Standard Deviation 13.8
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C29D1(n= 2, 36)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C5D1(n= 154, 230)	21.21 Units on a scale	Standard Deviation 26.63
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C30D1(n= 1, 30)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C16D1(n= 13, 105)	20.51 Units on a scale	Standard Deviation 21.68
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C31D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C9D1(n= 44, 135)	18.18 Units on a scale	Standard Deviation 28.26
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C17D1(n= 11, 93)	15.15 Units on a scale	Standard Deviation 22.92
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C33D1(n= 0, 15)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C2D1(n= 320, 347)	29.58 Units on a scale	Standard Deviation 30.44
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C18D1(n= 10, 89)	13.33 Units on a scale	Standard Deviation 23.31
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C35D1(n= 0, 10)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C10D1(n= 44, 136)	15.15 Units on a scale	Standard Deviation 23.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C19D1(n= 9, 80)	18.52 Units on a scale	Standard Deviation 24.22
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C6D1(n= 139, 214)	22.78 Units on a scale	Standard Deviation 25.39
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C20D1(n= 9, 74)	25.93 Units on a scale	Standard Deviation 36.43
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: EOT(n= 250, 226)	30.80 Units on a scale	Standard Deviation 32.97
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C11D1(n= 34, 123)	14.71 Units on a scale	Standard Deviation 23.49
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C21D1(n= 8, 69)	12.50 Units on a scale	Standard Deviation 17.25
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: Survival FU 1 (n= 2, 1)	83.33 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: Baseline (n= 373, 402)	27.52 Units on a scale	Standard Deviation 30.41
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: Survival FU 1 (n= 2, 1)	66.67 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: Baseline (n= 373, 402)	27.94 Units on a scale	Standard Deviation 31.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C2D1(n= 320, 347)	27.76 Units on a scale	Standard Deviation 30.53
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C3D1(n= 239, 286)	25.87 Units on a scale	Standard Deviation 29.79
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C4D1(n= 211, 263)	23.45 Units on a scale	Standard Deviation 26.92
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C5D1(n= 154, 230)	22.32 Units on a scale	Standard Deviation 27.24
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C6D1(n= 139, 214)	21.50 Units on a scale	Standard Deviation 27.88
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C7D1(n= 81, 180)	24.63 Units on a scale	Standard Deviation 29.56
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C8D1(n=65, 158)	18.35 Units on a scale	Standard Deviation 24.54
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C9D1(n= 44, 135)	21.48 Units on a scale	Standard Deviation 28.35
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C10D1(n= 44, 136)	21.57 Units on a scale	Standard Deviation 28.84
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C11D1(n= 34, 123)	20.05 Units on a scale	Standard Deviation 27.9
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C12D1(n= 26, 122)	16.67 Units on a scale	Standard Deviation 25.8
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C13D1(n= 17, 113)	19.76 Units on a scale	Standard Deviation 25.05
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C14D1(n= 18, 115)	22.03 Units on a scale	Standard Deviation 29.58
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C15D1(n= 15, 106)	19.18 Units on a scale	Standard Deviation 25.18
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C16D1(n= 13, 105)	21.90 Units on a scale	Standard Deviation 26.89
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C17D1(n= 11, 93)	22.22 Units on a scale	Standard Deviation 27.51
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C18D1(n= 10, 89)	22.10 Units on a scale	Standard Deviation 27.5
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C19D1(n= 9, 80)	24.58 Units on a scale	Standard Deviation 29.88
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C20D1(n= 9, 74)	21.17 Units on a scale	Standard Deviation 27.9
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C21D1(n= 8, 69)	21.26 Units on a scale	Standard Deviation 31.3
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C22D1(n= 8, 62)	18.82 Units on a scale	Standard Deviation 25.34
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C23D1(n= 8, 62)	18.82 Units on a scale	Standard Deviation 23.86
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C24D1(n= 5, 61)	19.67 Units on a scale	Standard Deviation 28.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C25D1(n= 3, 55)	16.97 Units on a scale	Standard Deviation 26.35
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C26D1(n= 2, 50)	18.67 Units on a scale	Standard Deviation 26.22
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C27D1(n= 3, 49)	14.29 Units on a scale	Standard Deviation 21.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C28D1(n= 2, 44)	15.15 Units on a scale	Standard Deviation 25.37
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C29D1(n= 2, 36)	21.30 Units on a scale	Standard Deviation 26.61
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C30D1(n= 1, 30)	16.67 Units on a scale	Standard Deviation 30.01
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C31D1(n= 0, 23)	11.59 Units on a scale	Standard Deviation 21.58
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C32D1(n= 0, 23)	20.29 Units on a scale	Standard Deviation 27.96
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C33D1(n= 0, 15)	11.11 Units on a scale	Standard Deviation 27.22
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C34D1(n= 0, 14)	30.95 Units on a scale	Standard Deviation 33.24
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C35D1(n= 0, 10)	26.67 Units on a scale	Standard Deviation 34.43
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C36D1(n= 0, 8)	20.83 Units on a scale	Standard Deviation 35.36
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C37D1(n= 0, 5)	33.33 Units on a scale	Standard Deviation 40.82
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: EOT(n= 250, 226)	32.01 Units on a scale	Standard Deviation 33.89
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts	Pain in Other Parts: Pro Week 6 Pd(n= 0,1)	0.00 Units on a scale	—

Secondary

EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C4D1(n= 221, 272)	28.05 Units on a scale	Standard Deviation 29.94
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C22D1(n= 7, 66)	23.81 Units on a scale	Standard Deviation 16.26
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C12D1(n= 30, 129)	30.00 Units on a scale	Standard Deviation 25.3
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C23D1(n= 8, 64)	16.67 Units on a scale	Standard Deviation 17.82
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C7D1(n= 86, 185)	31.01 Units on a scale	Standard Deviation 30.59
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C24D1(n= 5, 62)	13.33 Units on a scale	Standard Deviation 18.26
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C13D1(n= 19, 121)	26.32 Units on a scale	Standard Deviation 21.02
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C25D1(n= 3, 58)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C3D1(n= 250, 300)	25.60 Units on a scale	Standard Deviation 29.16
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C26D1(n= 2, 53)	16.67 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C14D1(n= 18, 119)	25.93 Units on a scale	Standard Deviation 21.56
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C27D1(n= 3, 50)	11.11 Units on a scale	Standard Deviation 19.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C8D1(n=70, 167)	35.24 Units on a scale	Standard Deviation 26.55
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C28D1(n= 2, 46)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C15D1(n= 15, 110)	24.44 Units on a scale	Standard Deviation 15.26
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C29D1(n= 2, 38)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C5D1(n= 165, 235)	29.29 Units on a scale	Standard Deviation 28.94
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C16D1(n= 13, 105)	20.51 Units on a scale	Standard Deviation 16.88
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C9D1(n= 50, 150)	36.00 Units on a scale	Standard Deviation 29.23
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C17D1(n= 11, 95)	21.21 Units on a scale	Standard Deviation 16.82
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C2D1(n= 335, 358)	25.57 Units on a scale	Standard Deviation 29.63
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C18D1(n= 10, 90)	23.33 Units on a scale	Standard Deviation 22.5
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C10D1(n= 47, 143)	36.17 Units on a scale	Standard Deviation 30.16
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C19D1(n= 9, 82)	14.81 Units on a scale	Standard Deviation 17.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C6D1(n= 147, 221)	31.97 Units on a scale	Standard Deviation 30.69
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C20D1(n= 9, 78)	22.22 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: EOT(n= 262, 244)	31.81 Units on a scale	Standard Deviation 31.53
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C11D1(n= 37, 129)	27.93 Units on a scale	Standard Deviation 24.23
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C21D1(n= 9, 73)	29.63 Units on a scale	Standard Deviation 20.03
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: Survival FU 1 (n= 2, 1)	50.00 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: Baseline (n= 386, 406)	19.26 Units on a scale	Standard Deviation 28.94
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: Survival FU 1 (n= 2, 1)	33.33 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: Baseline (n= 386, 406)	19.21 Units on a scale	Standard Deviation 27.77
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C2D1(n= 335, 358)	20.02 Units on a scale	Standard Deviation 27.21
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C3D1(n= 250, 300)	17.78 Units on a scale	Standard Deviation 25.04
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C4D1(n= 221, 272)	17.77 Units on a scale	Standard Deviation 25.75
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C5D1(n= 165, 235)	18.44 Units on a scale	Standard Deviation 25.97
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C6D1(n= 147, 221)	17.50 Units on a scale	Standard Deviation 25.34
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C7D1(n= 86, 185)	18.02 Units on a scale	Standard Deviation 25.29
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C8D1(n=70, 167)	17.56 Units on a scale	Standard Deviation 25.3
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C9D1(n= 50, 150)	15.78 Units on a scale	Standard Deviation 24.02
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C10D1(n= 47, 143)	18.18 Units on a scale	Standard Deviation 25.86
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C11D1(n= 37, 129)	17.05 Units on a scale	Standard Deviation 24.69
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C12D1(n= 30, 129)	17.57 Units on a scale	Standard Deviation 23.96
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C13D1(n= 19, 121)	17.91 Units on a scale	Standard Deviation 25.83
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C14D1(n= 18, 119)	17.09 Units on a scale	Standard Deviation 23.72
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C15D1(n= 15, 110)	17.58 Units on a scale	Standard Deviation 21.99
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C16D1(n= 13, 105)	17.14 Units on a scale	Standard Deviation 24.07
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C17D1(n= 11, 95)	19.30 Units on a scale	Standard Deviation 26.44
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C18D1(n= 10, 90)	18.15 Units on a scale	Standard Deviation 26.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C19D1(n= 9, 82)	20.33 Units on a scale	Standard Deviation 26.06
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C20D1(n= 9, 78)	17.52 Units on a scale	Standard Deviation 26.17
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C21D1(n= 9, 73)	18.72 Units on a scale	Standard Deviation 25.45
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C22D1(n= 7, 66)	15.66 Units on a scale	Standard Deviation 23.55
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C23D1(n= 8, 64)	20.31 Units on a scale	Standard Deviation 22.71
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C24D1(n= 5, 62)	20.43 Units on a scale	Standard Deviation 22.87
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C25D1(n= 3, 58)	18.39 Units on a scale	Standard Deviation 20.87
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C26D1(n= 2, 53)	20.13 Units on a scale	Standard Deviation 25.6
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C27D1(n= 3, 50)	19.33 Units on a scale	Standard Deviation 24.36
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C28D1(n= 2, 46)	19.57 Units on a scale	Standard Deviation 22.85
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C29D1(n= 2, 38)	19.30 Units on a scale	Standard Deviation 22.77
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C30D1(n= 1, 31)	20.43 Units on a scale	Standard Deviation 28.12
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C31D1(n= 0, 24)	23.61 Units on a scale	Standard Deviation 26.88
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C32D1(n= 0, 23)	18.84 Units on a scale	Standard Deviation 22.08
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C33D1(n= 0, 16)	22.92 Units on a scale	Standard Deviation 20.07
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C34D1(n= 0, 14)	19.05 Units on a scale	Standard Deviation 21.54
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C35D1(n= 0, 11)	15.15 Units on a scale	Standard Deviation 17.41
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C36D1(n= 0, 8)	8.33 Units on a scale	Standard Deviation 15.43
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C37D1(n= 0, 5)	26.67 Units on a scale	Standard Deviation 27.89
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: C38D1(n= 0, 2)	16.67 Units on a scale	Standard Deviation 23.57
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: EOT(n= 262, 244)	19.54 Units on a scale	Standard Deviation 27.32
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy	Peripheral Neuropathy: Pro Week 6 Pd(n= 0,1)	66.67 Units on a scale	—

Secondary

EORTC QLQ-LC13 Questionnaire Score: Sore Mouth

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C4D1(n= 219, 270)	14.00 Units on a scale	Standard Deviation 22.95
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C22D1(n= 8, 67)	4.17 Units on a scale	Standard Deviation 11.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C12D1(n= 30, 129)	2.22 Units on a scale	Standard Deviation 8.46
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C23D1(n= 8, 64)	4.17 Units on a scale	Standard Deviation 11.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C7D1(n= 87, 185)	9.20 Units on a scale	Standard Deviation 20.77
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C24D1(n= 5, 62)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C13D1(n= 19, 121)	1.75 Units on a scale	Standard Deviation 7.65
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C25D1(n= 3, 57)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C3D1(n= 252, 297)	14.29 Units on a scale	Standard Deviation 23.59
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C26D1(n= 3, 53)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C14D1(n= 18, 119)	3.70 Units on a scale	Standard Deviation 10.78
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C27D1(n= 3, 50)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C8D1(n=70, 166)	8.57 Units on a scale	Standard Deviation 16.73
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C28D1(n= 2, 46)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C15D1(n= 15, 110)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C29D1(n= 2, 38)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C5D1(n= 165, 234)	11.31 Units on a scale	Standard Deviation 19.65
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C30D1(n= 1, 31)	0.00 Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C16D1(n= 13, 106)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C31D1(n= 0, 24)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C9D1(n= 50, 151)	6.00 Units on a scale	Standard Deviation 17.42
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C32D1(n= 0, 23)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C17D1(n= 11, 95)	3.03 Units on a scale	Standard Deviation 10.05
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C33D1(n= 0, 16)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C2D1(n= 335, 357)	15.52 Units on a scale	Standard Deviation 25.75
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C34D1(n= 0, 14)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C18D1(n= 10, 90)	3.33 Units on a scale	Standard Deviation 10.54
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C35D1(n= 0, 11)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C10D1(n= 47, 143)	7.09 Units on a scale	Standard Deviation 15.44
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C36D1(n= 0, 8)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C19D1(n= 9, 82)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C37D1(n= 0, 5)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C6D1(n= 148, 218)	13.29 Units on a scale	Standard Deviation 23.24
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C38D1(n= 0, 2)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C20D1(n= 9, 78)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: EOT(n= 265, 243)	11.57 Units on a scale	Standard Deviation 22.85
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C11D1(n= 37, 130)	4.50 Units on a scale	Standard Deviation 13.97
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: Pro Week 6 Pd(n= 0,1)	NA Units on a scale	—
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C21D1(n= 9, 73)	0.00 Units on a scale	Standard Deviation 0
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: Survival FU 1 (n= 2, 1)	16.67 Units on a scale	Standard Deviation 23.57
Docetaxel	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: Baseline (n= 387, 404)	5.68 Units on a scale	Standard Deviation 16.34
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: Survival FU 1 (n= 2, 1)	0.00 Units on a scale	—
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: Baseline (n= 387, 404)	4.95 Units on a scale	Standard Deviation 15.32
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C2D1(n= 335, 357)	7.10 Units on a scale	Standard Deviation 18.17
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C3D1(n= 252, 297)	5.61 Units on a scale	Standard Deviation 14.18
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C4D1(n= 219, 270)	4.81 Units on a scale	Standard Deviation 13.99
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C5D1(n= 165, 234)	4.27 Units on a scale	Standard Deviation 13.49
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C6D1(n= 148, 218)	4.13 Units on a scale	Standard Deviation 13.89
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C7D1(n= 87, 185)	5.59 Units on a scale	Standard Deviation 15.5
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C8D1(n=70, 166)	5.02 Units on a scale	Standard Deviation 14.96
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C9D1(n= 50, 151)	3.09 Units on a scale	Standard Deviation 14.06
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C10D1(n= 47, 143)	3.96 Units on a scale	Standard Deviation 14.53
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C11D1(n= 37, 130)	3.33 Units on a scale	Standard Deviation 12.35
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C12D1(n= 30, 129)	4.65 Units on a scale	Standard Deviation 14.87
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C13D1(n= 19, 121)	5.23 Units on a scale	Standard Deviation 15.52
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C14D1(n= 18, 119)	5.32 Units on a scale	Standard Deviation 15.64
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C15D1(n= 15, 110)	4.24 Units on a scale	Standard Deviation 13.63
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C16D1(n= 13, 106)	3.77 Units on a scale	Standard Deviation 16.15
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C17D1(n= 11, 95)	6.32 Units on a scale	Standard Deviation 17.73
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C18D1(n= 10, 90)	3.70 Units on a scale	Standard Deviation 11.66
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C19D1(n= 9, 82)	4.47 Units on a scale	Standard Deviation 12.57
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C20D1(n= 9, 78)	5.56 Units on a scale	Standard Deviation 15.59
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C21D1(n= 9, 73)	7.76 Units on a scale	Standard Deviation 17.14
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C22D1(n= 8, 67)	6.47 Units on a scale	Standard Deviation 17.64
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C23D1(n= 8, 64)	6.25 Units on a scale	Standard Deviation 16.67
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C24D1(n= 5, 62)	5.38 Units on a scale	Standard Deviation 13.75
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C25D1(n= 3, 57)	3.51 Units on a scale	Standard Deviation 10.32
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C26D1(n= 3, 53)	6.92 Units on a scale	Standard Deviation 13.65
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C27D1(n= 3, 50)	4.00 Units on a scale	Standard Deviation 10.94
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C28D1(n= 2, 46)	4.35 Units on a scale	Standard Deviation 11.35
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C29D1(n= 2, 38)	3.51 Units on a scale	Standard Deviation 10.37
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C30D1(n= 1, 31)	4.30 Units on a scale	Standard Deviation 11.36
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C31D1(n= 0, 24)	4.17 Units on a scale	Standard Deviation 11.26
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C32D1(n= 0, 23)	4.35 Units on a scale	Standard Deviation 11.48
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C33D1(n= 0, 16)	4.17 Units on a scale	Standard Deviation 11.39
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C34D1(n= 0, 14)	9.52 Units on a scale	Standard Deviation 15.63
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C35D1(n= 0, 11)	6.06 Units on a scale	Standard Deviation 13.48
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C36D1(n= 0, 8)	4.17 Units on a scale	Standard Deviation 11.78
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C37D1(n= 0, 5)	13.33 Units on a scale	Standard Deviation 29.81
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: C38D1(n= 0, 2)	0.00 Units on a scale	Standard Deviation 0
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: EOT(n= 265, 243)	7.00 Units on a scale	Standard Deviation 17.18
Atezolizumab	EORTC QLQ-LC13 Questionnaire Score: Sore Mouth	Sore Mouth: Pro Week 6 Pd(n= 0,1)	66.67 Units on a scale	—

Secondary

Maximum Observed Serum Atezolizumab Concentration (Cmax)

Time frame: Predose (Hr 0), 30 minutes (min) post-infusion (infusion duration: 60 min) on Cycle 1 Day 1 (1 Cycle=21 days)

Population: Pharmacokinetic (PK) evaluable population included participants who received atezolizumab treatment and had at least one measurable PK concentration.

Arm	Measure	Value (MEAN)	Dispersion
Docetaxel	Maximum Observed Serum Atezolizumab Concentration (Cmax)	400 Microgram per milliliter (mcg/mL)	Standard Deviation 127

Secondary

Minimum Observed Serum Atezolizumab Concentration (Cmin)

Time frame: Predose (Hr 0) on Day 1 of Cycles 1, 2, 3, 4, 8, 16, 24, 32, EOT (approximately 2.25 years); 120 days after EOT (approximately 2.25 years) (1 Cycle=21 days)

Population: PK evaluable participants. Here, 'n' signifies those participants evaluated for this measure at specific time point. All 606 participants contributed to the endpoint but not all completed evaluation of every timepoint. Convention 'CxDx' refers to cycle number and day number.

Arm	Measure	Group	Value (MEAN)	Dispersion
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	C32D1 (n= 11)	277 mcg/mL	Standard Deviation 117
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	EOT (n= 347)	144 mcg/mL	Standard Deviation 101
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	120 days after EOT (n= 124)	10.4 mcg/mL	Standard Deviation 20
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	C1D1 (n= 593)	2.59 mcg/mL	Standard Deviation 30.9
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	C2D1 (n= 534)	83.2 mcg/mL	Standard Deviation 31
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	C3D1 (n= 445)	130 mcg/mL	Standard Deviation 55.8
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	C4D1 (n= 405)	158 mcg/mL	Standard Deviation 66.4
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	C8D1 (n= 222)	205 mcg/mL	Standard Deviation 99.4
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	C16D1 (n= 132)	226 mcg/mL	Standard Deviation 105
Docetaxel	Minimum Observed Serum Atezolizumab Concentration (Cmin)	C24D1 (n= 63)	250 mcg/mL	Standard Deviation 99.8

Secondary

Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab

Time frame: Baseline up to approximately 2.25 years (assessed at predose [Hour {Hr} 0] on Day 1 of Cycles 1, 2, 3, 4, 8, 16, then every 8 cycles up to end of treatment (EOT) [approximately 2.25 years]; 120 days after EOT [approximately 2.25 years] [1 Cycle=21 days])

Population: ATA evaluable population included all participants who received atezolizumab treatment and had at least one post treatment ATA result.

Arm	Measure	Value (NUMBER)
Docetaxel	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab	30.4 Percentage of Participants

Secondary

Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT

PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 millimeters (mm), or presence of new lesions.

Time frame: Baseline up to PD or Death (up to approximately 2.25 years)

Population: The PP-ITT analysis set

Arm	Measure	Value (NUMBER)
Docetaxel	Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT	88.2 Percentage of Participants
Atezolizumab	Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT	89.4 Percentage of Participants

Secondary

Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT

Objective response is defined as a complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.

Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)

Population: The PP-ITT analysis set.

Arm	Measure	Value (NUMBER)
Docetaxel	Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT	13.4 Percentage of Participants
Atezolizumab	Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT	13.6 Percentage of Participants

Secondary

Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT

Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)

Population: SP-ITT analysis set.

Arm	Measure	Value (NUMBER)
Docetaxel	Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT	11.8 Percentage of Participants
Atezolizumab	Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT	13.7 Percentage of Participants

Secondary

Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP

Objective response is defined as a CR or PR as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.

Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)

Population: The TC1/2/3 or IC1/2/3 subgroup of PP

Arm	Measure	Value (NUMBER)
Docetaxel	Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	16.2 Percentage of Participants
Atezolizumab	Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	17.8 Percentage of Participants

Secondary

Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP

PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.

Time frame: Baseline up to PD or Death (up to approximately 2.25 years)

Population: TC1/2/3 or IC1/2/3 subgroup of PP

Arm	Measure	Value (NUMBER)
Docetaxel	Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP	86.9 Percentage of Participants
Atezolizumab	Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP	89.6 Percentage of Participants

Secondary

PFS as Determined by Investigator Using RECIST v1.1: SP-ITT

PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.

Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years)

Population: SP-ITT analysis set.

Arm	Measure	Value (MEDIAN)
Docetaxel	PFS as Determined by Investigator Using RECIST v1.1: SP-ITT	3.8 Months
Atezolizumab	PFS as Determined by Investigator Using RECIST v1.1: SP-ITT	2.7 Months

p-value: 0.498195% CI: [0.85, 1.08]Log Rank

Secondary

PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP

Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)

Population: The TC1/2/3 or IC1/2/3 subgroup of PP

Arm	Measure	Value (MEDIAN)
Docetaxel	PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	4.1 Months
Atezolizumab	PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP	2.8 Months

Comparison: Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.p-value: 0.380695% CI: [0.74, 1.12]Log Rank

Comparison: Unstratified Analysisp-value: 0.324995% CI: [0.74, 1.1]Log Rank

Secondary

Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT

Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years)

Population: The PP-ITT analysis set.

Arm	Measure	Value (MEDIAN)
Docetaxel	Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT	4.0 Months
Atezolizumab	Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT	2.8 Months

Comparison: Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.p-value: 0.492895% CI: [0.82, 1.1]Log Rank

Comparison: Unstratified Analysisp-value: 0.359695% CI: [0.81, 1.08]Log Rank

Secondary

Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)

TTD in patient-reported lung cancer symptoms (pain in chest or in arm/shoulder, dyspnea, or cough) was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the symptoms. A \>/=10-point change in the score perceived by participants was considered as clinically significant. The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity.

Time frame: Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years) (1 Cycle = 21 days)

Population: The PP-ITT analysis set.

Arm	Measure	Group	Value (MEDIAN)
Docetaxel	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Pain in Chest	8.3 Months
Docetaxel	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Cough	5.6 Months
Docetaxel	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Dyspnea	2.1 Months
Docetaxel	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Arm/Shoulder Pain	6.2 Months
Atezolizumab	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Arm/Shoulder Pain	8.3 Months
Atezolizumab	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Pain in Chest	18.0 Months
Atezolizumab	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Dyspnea	1.8 Months
Atezolizumab	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)	Cough	5.5 Months

Comparison: Pain in Chest: Stratified analysis based on the strata of IC levels per IxRS, the number of prior chemotherapy regimens per IxRS, and histology per eCRF.p-value: 0.011195% CI: [0.55, 0.93]Log Rank

Comparison: Cough: Unstratified Analysisp-value: 0.630595% CI: [0.84, 1.33]Log Rank

Comparison: Dyspnea: Unstratified Analysisp-value: 0.740695% CI: [0.81, 1.16]Log Rank

Comparison: Arm/Shoulder Painp-value: 0.522195% CI: [0.73, 1.17]Log Rank

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

OS: SP-ITT

OS: TC1/2/3 or IC1/2/3 Subgroup of PP

OS: TC1/2/3 Or IC1/2/3 Subgroup of SP

OS: TC2/3 or IC2/3 Subgroup of SP

OS: TC3 or IC3 Subgroup of SP

Overall Survival (OS): PP-ITT

Percentage of Participants Who Died: PP-ITT

Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP

DOR as Determined by Investigator Using RECIST v1.1: SP ITT

DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP

Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT

EORTC QLQ-C30 Questionnaire Score: Functional Subscales

EORTC QLQ-C30 Questionnaire Score: GHS Scale

EORTC QLQ-C30 Questionnaire Score: Symptom Subscale

EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items

EORTC QLQ-LC13 Questionnaire Score: Alopecia

EORTC QLQ-LC13 Questionnaire Score: Coughing

EORTC QLQ-LC13 Questionnaire Score: Dysphagia

EORTC QLQ-LC13 Questionnaire Score: Dyspnea

EORTC QLQ-LC13 Questionnaire Score: Hemoptysis

EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder

EORTC QLQ-LC13 Questionnaire Score: Pain in Chest

EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts

EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy

EORTC QLQ-LC13 Questionnaire Score: Sore Mouth

Maximum Observed Serum Atezolizumab Concentration (Cmax)

Minimum Observed Serum Atezolizumab Concentration (Cmin)

Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab

Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT

Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT

Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT

Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP

Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP

PFS as Determined by Investigator Using RECIST v1.1: SP-ITT

PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP

Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT

Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13)